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Substrates of a ubiquitin-dependent proteolytic system called
the N-end rule pathway include proteins with destabilizing
N-terminal residues. N-recognins, the pathway’s ubiquitin
ligases, contain three substrate-binding sites. The type-1 site is
specific for basic N-terminal residues (Arg, Lys, and His). The
type-2 site is specific for bulky hydrophobicN-terminal residues
(Trp, Phe, Tyr, Leu, and Ile). We show here that the type-1/2
sites of UBR1, the sole N-recognin of the yeast Saccharomyces
cerevisiae, are located in the first 700 residues of the 1,950-
residue UBR1. These sites are distinct in that they can be selec-
tively inactivated by mutations, identified through a genetic
screen. Mutations inactivating the type-1 site are in the previ-
ously delineated 70-residue UBR motif characteristic of
N-recognins. Fluorescence polarization and surface plasmon
resonance were used to determine that UBR1 binds, with aKd of
1M, to either type-1 or type-2 destabilizing N-terminal resi-
dues of reporter peptides but does not bind to a stabilizing
N-terminal residue such asGly. A third substrate-binding site of
UBR1 targets an internal degron of CUP9, a transcriptional
repressor of peptide import. We show that the previously dem-
onstrated in vivo dependence of CUP9 ubiquitylation on the
binding of cognate dipeptides to the type-1/2 sites of UBR1 can
be reconstituted in a completely defined in vitro system.Wealso
found that purified UBR1 and CUP9 interact nonspecifically
and that specific binding (which involves, in particular, the
binding by cognate dipeptides to theUBR1 type-1/2 sites) canbe
restored either by a chaperone such as EF1A or throughmacro-
molecular crowding.
The N-end rule relates the in vivo half-life of a protein to the
identity of its N-terminal residue. The ubiquitin (Ub)3-depend-
entN-end rule pathway recognizes several kinds of degradation
signals (degrons), including a set called N-degrons (Fig. 1A)
(1–9). Although prokaryotes lack the Ub system, they still con-
tain theN-end rule pathway, albeit Ub-independent versions of
it (10–18). In eukaryotes, an N-degron consists of three deter-
minants: a destabilizing N-terminal residue of a protein sub-
strate, one (or more) of its internal Lys residues (the site of
formation of a poly-Ub chain), and a conformationally flexible
region in a vicinity of this residue (1, 19–23). The N-end rule
has a hierarchic structure (Fig. 1A). In eukaryotes, N-terminal
Asn andGln are tertiary destabilizing residues in that they func-
tion through their enzymatic deamidation, to yield the second-
ary destabilizing N-terminal residues Asp andGlu (24, 25). The
destabilizing activity of N-terminal Asp and Glu requires their
conjugation to Arg, one of the primary destabilizing residues,
by Arg-tRNA-protein transferase (arginyl-transferase or
R-transferase) (5–7, 26, 27). In mammals and other eukaryotes
that produce nitric oxide (NO), the set of arginylated residues
contains not only Asp and Glu but also N-terminal Cys (28),
which is arginylated after its oxidation to Cys-sulfinate or Cys-
sulfonate (27). The in vivo oxidation ofN-terminal Cys requires
NO, as well as oxygen (O2) or its derivatives (Fig. 1A) (6, 7, 29).
The N-end rule pathway is thus a sensor of NO, through the
ability of this pathway to destroy proteins with N-terminal Cys,
at rates controlled by NO, O2, and their derivatives.
E3 Ub ligases of the N-end rule pathway, called N-recognins
(1, 8, 29–37), recognize (bind to) primary destabilizing N-ter-
minal residues, including Arg (Fig. 1A). (The term “Ub ligase”
denotes either an E2-E3 holoenzyme or its E3 component.) At
least four N-recognins, including UBR1, mediate the N-end
rule pathway inmammals (30–33, 36). The knownN-recognins
share an 70-residue motif called the UBR box. Mouse UBR1
and UBR2 are sequelogous (similar in sequence) 200-kDa
RING-type E3 Ub ligases that are 47% identical. Several other
UBR-containing N-recognins, either confirmed or putative
ones, are HECT-type or SCF-type E3 Ub ligases that share the
UBR motif with the RING-type UBR1/UBR2 but are largely
nonsequelogous to them otherwise (29–33). (A note on termi-
nology: “sequelog” and “spalog” denote, respectively, a
sequence that is similar, to a specified extent, to another
sequence, and a three-dimensional structure that is similar, to a
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specified extent, to another three-dimensional structure (38).
Besides their usefulness as separate terms for sequence and spa-
tial similarities, the rigor-conferring advantage of sequelog and
spalog is their evolutionary neutrality, in contrast to interpre-
tation-laden terms such as “homolog,” “ortholog,” and “para-
log.” The latter terms are compatible with the sequelog/spalog
terminology and can be used to convey understanding about
functions and common descent, if this (additional) information
is available (38).)
The N-end rule pathway of S. cerevisiae is mediated by a
single N-recognin, UBR1, a 225-kDa sequelog of mammalian
UBR1 and UBR2 (Fig. 1, A and C) (8, 9). Saccharomyces cerevi-
siae UBR1 (Fig. 1C) contains at least three substrate-binding
sites. The type-1 site is specific for basic N-terminal residues of
protein substrates (Arg, Lys, andHis), whereas the type-2 site is
specific for bulky hydrophobic N-terminal residues (Trp, Phe,
Tyr, Leu, and Ile). The third binding site of UBR1 targets pro-
teins through their internal (non-N-terminal) degron, and is
allosterically “activated” through a conformational change that
is caused by the binding of short peptides to the two other
binding sites of UBR1, type-1 and type-2. The known substrate
of the third binding site ofUBR1 is CUP9 (8, 39, 40), a transcrip-
tional repressor whose regulon includes PTR2 (41), a gene en-
coding transporter of di- and tripeptides. The reversal of UBR1
autoinhibition by imported peptides accelerates the UBR1-de-
pendent ubiquitylation of CUP9, leads to its faster degradation,
and thereby causes a derepression of PTR2. The resulting pos-
itive feedback circuit allows S. cerevisiae to detect the presence
of extracellular peptides and to react by increasing their uptake
(8, 40). ClpS, a 12-kDa prokaryotic N-recognin, is an “adaptor”
protein thatmediates the (Ub-independent) targeting of N-end
rule substrates in bacteria (13–15). ClpS recognizes type-2
(bulky hydrophobic) N-terminal residues and contains a region
of sequelogy to the 225-kDa yeast UBR1, near its UBR box (2,
13, 42). This similarity and other common features of eukary-
otic and prokaryotic N-end rule pathways (1, 2, 29) suggest that
at least some N-degrons, N-recognins, and relevant “down-
stream” proteases had evolved before the split between
eukaryotes and prokaryotes.
The functions of the N-end rule pathway include: (i) the
sensing of heme, through inhibition of the ATE1 R-transfer-
ase, in both yeast and mammals, by hemin (Fe3-heme),
which also inhibits N-recognins, the latter at least in yeast (4)
(Fig. 1A); (ii) the sensing of NO and oxygen and the resulting
control of signaling by transmembrane receptors through
the conditional, NO/O2-mediated degradation of G-protein
regulators RGS4, RGS5, and RGS16 (6, 7); (iii) regulation of
import of short peptides through the degradation, modu-
lated by peptides, of CUP9, the repressor of import (8, 40);
(iv) fidelity of chromosome segregation through degradation
of a separase-produced cohesin fragment (43); (v) regulation
of apoptosis through degradation of a caspase-processed
inhibitor of apoptosis (44, 45); (vi) a multitude of processes
mediated by the transcription factor c-FOS, a conditional
substrate of the N-end rule pathway (46); (vii) regulation of
the human immunodeficiency virus replication cycle
through degradation of human immunodeficiency virus
integrase (47); and (viii) regulation of meiosis, spermatogen-
esis, neurogenesis, and cardiovascular development in mam-
mals (6, 7, 27, 31, 33) and leaf senescence in plants (48).
Mutations in human UBR1 (Fig. 1A) (29, 32, 33) are the cause
of Johansson-Blizzard syndrome, which includes mental
retardation, physical malformations, and severe pancreatitis
(49). The abnormalities of UBR1/ mice (30) include pan-
creatic insufficiency (49), a less severe counterpart of this
defect in human Johansson-Blizzard syndrome (UBR1/)
patients.
In this study,we used a genetic screen to probe the type-1 and
type-2 substrate-binding sites of S. cerevisiae UBR1. This anal-
ysis demonstrated a modular organization of these sites, which
could be selectively inactivated by specific mutations. We also
characterized physical interactions between UBR1 and CUP9
that involve the internal (non-N-terminal) degron of CUP9,
and we employed a completely defined in vitro system to probe
the conditional (modulated by dipeptides) polyubiquitylation
of CUP9 by the UBR1-RAD6 Ub ligase. In addition, we used
both fluorescence polarization (FP) and surface plasmon reso-
nance (SPR) to determine the affinities of purified UBR1 for
specific N-terminal residues of model peptides. The results
indicated, among other things, that at least the bulk of the
observed in vivo specificity of UBR1 for N-end rule substrates
(1, 2, 29) (Fig. 1,A andC) stems from differences in the physical
affinity of UBR1 for destabilizing versus stabilizing N-terminal
residues in the N-end rule.
EXPERIMENTAL PROCEDURES
Yeast Strains, Media, and Genetic Techniques—Synthetic
yeast media (50) contained 0.67% yeast nitrogen base without
amino acids (Difco) and either 2% glucose (SD medium) or 2%
galactose (SG medium). Synthetic media lacking appropriate
nutrients were used to select for (and maintain) specific plas-
mids. Cells were also grown in rich medium (YPD) (51). The S.
cerevisiae strains were YPH500 (MAT ura3-52 lys2-801 ade2-
101 his3-200 trp1-63 his3-200 leu2-1), JD52 (MATa
trp1-63 ura3-52 his3-200 leu2-3,112 lys2-801), JD55 (MATa
ubr1::HIS3 trp1-63 ura3-52 his3-200 leu2-3,112 lys2-801)
(52), SC295 (MATaGAL4GAL80 ura3-52, leu2-3,112 reg1-501
gal1 pep4-3) (8), and PJ69–4A (MATa trp1-901 leu2–3,112
ura3-52 his3-200 gal4 gal80GAL2-ADE2LYS2::GAL1-HIS3
met2::GAL7-lacZ). The medium for dipeptide import assays
wasmethionine-lacking SD containing allantoin (1mg/ml) and
the toxic dipeptide L-leucyl-L-ethionine (Leu-Eth; 37 M) (39).
To induce the PCUP1 promoter, CuSO4 was added to a final
concentration of 0.1 mM (52). The XGal colony overlay assay
was performed using 5-bromo-4-chloro-3-indolyl--D-galac-
topyranoside (XGal) at 0.1 mg/ml, as described (53). Transfor-
mation of S. cerevisiaewas carried out using the lithium acetate
method (50).
Reporter Plasmids—Five sets of reporter plasmids were used.
Details of their construction are available upon request.
pUB23-X high copy plasmids expressedUb-X-eK--galactosid-
ase fusions (denoted below as Ub-X-gal) from the galactose-
inducible PGAL1 promoter (19, 54). pBAX plasmids expressed
Ub-X-eK-ha-URA3 fusions (XArg or Leu), denoted below as
Ub-X-URA3. The largely cotranslational deubiquitylation of
these Ub fusions (55) yielded the corresponding X-gal and
UBR1 Ubiquitin Ligase
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X-URA3 reporter proteins. pBAX plasmids were constructed
from pBAM, a pRS314-based low copy plasmid expressing Ub-
Met-eK-ha-URA3 (tagged with the ha epitope (50)) from the
PCUP1 promoter (56). The term eK (extension (e) bearing lysines
(K)) denotes an 40-residue, Escherichia coli Lac repressor-
derived sequence (21, 54, 56). pDSRULB was constructed by
subcloning the 5.4-kb ScaI fragment from pUB23-L (encoding
Ub-Leu-gal) into the SmaI site of pBAR, encoding Ub-Arg-
URA3. The resulting low copy TRP1-marked pRS314 plasmid
expressed Ub-Arg-URA3 from the PCUP1 promoter and
Ub-Leu-gal from the PGAL1 promoter. The similarly con-
structed pDSLURB expressed Ub-Leu-URA3 and Ub-Arg-
gal. The UPR (Ub/protein/reference) plasmids (21, 40, 57) for
expression in S. cerevisiae, termed pBAXUPR, were based on
the low copy pRS314 vector (58) and were constructed using
PCR. A pBAXUPR plasmid expressed DHFRha-UbR48-X-eK-
ha-URA3 (denoted below as DHFR-Ub-X-URA3) from the
PCUP1 promoter (where X  Met, Arg, Leu, Glu, Lys, His, Ile,
Phe, Tyr, or Trp). The analogous UPR-based plasmids, termed
pXgalUPR, expressed DHFRha-UbR48-X-eK-gal (X  Met,
Arg, or Leu), denoted as DHFR-Ub-X-gal. pXgalUPR were
constructed by cutting an appropriate pBAXUPR plasmid with
BamHI and SmaI, recovering the vector-containing fragment,
and ligating it to the 3.8-kb gal-encoding fragment produced
from pUB23-M using BamHI and ScaI.
UBR1 Plasmids—S. cerevisiae UBR1 plasmids encoding
wild-type or mutated UBR1 included pRBUBR1, pRB208,
pFLAGUBR1SBX, pFLAGNT1UBR1, pUBR1NT1140FLAG,
p209NTUBR1FLAG, p454NTUBR1FLAG, p710NTUBR1FLAG,
p866NTUBR1FLAG, and p1002NTUBR1FLAG. Details of con-
struction are available upon request.UBR1 alleles were expressed
from the PADH1 promoter of the high copy LEU2-marked
YEplac181 vector (59) in SC295, a protease-deficient S. cerevisiae
strain. UBR1 and its derivatives that were encoded by the above
plasmids carried either the ha epitope (pRBUBR1 and pRB208) or
theFLAGepitope.pRB208andpRBUBR1(aderivativeofpRB208)
encoded full-length, C-terminally ha-tagged S. cerevisiae UBR1
(UBR1ha). pFLAGUBR1SBX encoded fUBR1, the N-terminally
FLAG-tagged full-length UBR1. pFLAGNT1UBR1 encoded
fUBR11–717, the N-terminally FLAG-tagged C-terminally
truncated variant of UBR1. The design and expression of
fUBR1 and fUBR11–717 were described (8). The plasmids
p209NTUBR1FLAG, p454NTUBR1FLAG, p710NTUBR1FLAG,
p866NTUBR1FLAG, and p1002NTUBR1FLAG, which encoded,
respectively, UBR1209–1140f, UBR1454–1140f, UBR1710–1140f,
UBR1866–1140f, and UBR11002–1140f, were derivatives of
pUBR1NT1140FLAG (8), a high copy plasmid that expressed
C-terminally FLAG-tagged UBR11–1140f from the yeast PADH1
promoter. The FLAG tag was located at the C terminus of the
UBR1derivatives except for the full-length fUBR1and fUBR11–717.
UBR1 test proteins remained intact in yeast extracts that were
prepared and incubated as described previously (8).
Expression and Purification of X-SCC1-GST—A set of three
pTYB12-X-SCC1-GST plasmids, which expressed Intein-CBD-
X-SCC1-GST fusions (X  Arg, Leu, or Met), was employed for
glutathione S-transferase (GST) pulldown assays. Details of con-
struction are available upon request. A specific pTYB12-X-SCC1-
GST plasmid was cotransformed into E. coli BL21(DE3) together
with pRI952, which expressed tRNAs for the codons AGG, AGA,
and AUA that are rare in E. coli (60). A fresh E. coli colony was
inoculated into LB medium (600 ml) containing ampicillin (0.1
mg/ml) and chloramphenicol (25 g/ml), followed by growth at
37 °C until A600 of 0.5–0.8. Isopropyl -D-thiogalactopyranoside
was then added to the final concentration of 0.4mM, followed by a
10-h incubation,with shaking, at 18 °C.The cellswere centrifuged
at 5,000  g for 10 min at 4 °C, washed once with phosphate-
buffered saline (PBS), and frozen in liquidN2. For isolation of pro-
teins, the cell pellet was thawed at 0 °C and then resuspended in
lysis buffer (0.1% Triton X-100, 0.5 M NaCl, 20 mM Tris-HCl, pH
8.5) containing protease inhibitor mixture (Roche Applied Sci-
ence) (6 ml of buffer per 1 g of pellet), and cells were disrupted by
sonication on ice. The suspension was centrifuged at 13,000 g
for 30 min. The supernatant was loaded onto a pre-equilibrated
chitin column (10-ml bed volume), at a rate not higher than 0.5
ml/min, and washed with 200 ml of column buffer (0.5 M NaCl, 1
mM EDTA, 20 mM Tris-HCl, pH 8.5), at 1 ml/min. The column
was then flushed quickly with 30 ml of freshly prepared cleavage
buffer (column buffer containing 40 mM dithiothreitol); the flow
was stopped, and the column was incubated at 23 °C for 16 h.
X-SCC1-GST proteins were eluted with 30 ml of column buffer,
concentrated with Centriplus (Millipore, Billerica, MA), and dia-
lyzed against column buffer at 4 °C. The resulting samples were
stored in small aliquots at80 °C. The presence of desired N-ter-
minal residues in the purified X-SCC1-GST proteins was verified
using N-terminal sequencing by Edman degradation. GST-CUP9
was expressed and purified as described (8).
Expression and Purification of fUBR1 and UBR11–1140f—To
express and purify theC-terminally FLAG-taggedUBR11–1140f, S.
cerevisiae (SC295) carrying pUBR1NT1140FLAG was grown to
A600 of1.5, and the cells were harvested by centrifugation. The
lysate was prepared as described (8), using lysis buffer (10% glyc-
erol, 0.05% Nonidet P-40, 0.2 M KCl, 50 mM HEPES, pH 7.1), fol-
lowedby the addition of anti-FLAGbeads (Sigma), 1-h incubation
withrocking,washingof thebeadswith lysisbuffer, and theelution
of UBR11–1140f with the FLAGpeptide at 0.2mg/ml in lysis buffer
lackingNonidetP-40.TheexpressionandpurificationofN-termi-
nally FLAG-tagged full-length UBR1 (fUBR1) were similar to that
of UBR11–1140f, with modifications. A single colony of SC295 S.
cerevisiae transformed with the pFLAGUBR1SBXwas inoculated
into 20 ml of yeast SDmedium and grown at 30 °C to A600 of1.
The 20-ml culture was re-inoculated into 2 liters of SD medium
andgrown toA600 of1, followedby the additionof equal volume
of yeast YPDmedium. The cells were grown for3more genera-
tions, until A600 of4, harvested by centrifugation, washed once
with cold 1 PBS, and frozen in liquid N2. Other procedures,
including purification, were identical to those with UBR11–1140f.
Concentrations of purified fUBR1 and UBR11–1140f were deter-
minedusing theProteinAssay reagent (Bio-Rad). Samples of puri-
fied fUBR1 andUBR11–1140f were frozen in liquidN2 and stored at
80 °C.
GST Pulldown Assays and Related Procedures—An SCC1-
based GST fusion protein (2 g) (see above) was diluted to
0.3 ml in PBS-based buffer (10% glycerol, 1% Triton X-100,
137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM
KH2PO4, pH 7.4) and incubated with 20 l of glutathione-
Sepharose-4B beads (Amersham Biosciences) for 30 min at
UBR1 Ubiquitin Ligase
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4 °C. The beads were washed once with 0.5 ml of PBS-based
buffer and twice with 0.5 ml of GST pulldown buffer (10%
glycerol, 0.05% Nonidet P-40, 50 mM NaCl, 50 mM HEPES,
pH 7.6). The washed beads, in 0.15 ml of the binding buffer,
were incubated at 4 °C for 1 h with 0.1 ml of S. cerevisiae
extract (5 mg/ml total protein) containing either fUBR1
(N-terminally FLAG-tagged UBR1) or its truncated deriva-
tives (see above) at the same concentration. These assays
were performed in either the presence or absence of specific
amino acids or amino acid derivatives, including dipeptides
(Sigma), at concentrations indicated in figure legends. Bind-
ing assays also contained ovalbumin (Sigma; at 0.1 mg/ml,
unless not stated otherwise), protease inhibitor mixture
(Sigma), and 50 M bestatin (Sigma). The beads were washed
twice with 0.2 ml of the binding buffer either containing or
lacking specific dipeptides, depending on whether a binding
assay contained them.Washed beads were resuspended in 30
l of SDS-PAGE loading buffer and heated at 95 °C for 4min,
and 15-l samples were subjected to SDS-10% PAGE, fol-
lowed by immunoblotting with anti-FLAG M2 antibody
(Sigma).
CUP9-based GST pulldown assays with fUBR1 were carried
out similarly except for the following: the total volumewas 0.26
ml, with 1 l of purified fUBR1 (0.4 mg/ml), either in binding
buffer (10% glycerol, 0.05% Nonidet P-40, 50 mM NaCl, 50 mM
HEPES, pH 7.5), or in binding buffer supplemented with 60 l
of S. cerevisiae“empty” extract (no FLAG-tagged UBR1), or in
GST-binding buffer containing ovalbumin (at 10 mg/ml); or in
0.2ml of binding buffer supplementedwith 60l of S. cerevisiae
extract containing fUBR1.WithUBR11–1140f, the assaywas per-
formed similarly, except that the reaction volume was 0.23 ml
(0.2 ml of binding buffer plus 30 l of extract from S. cerevisiae
that produced UBR11–1140f) or, alternatively, the same (30 l)
volume but containing 1 l of purified UBR11–1140f (at 0.2
mg/ml), and ovalbumin at 50 mg/ml, as described in figure
legends.
In another binding assay, we employed pyCUP9his6, a puri-
fied (after overexpression in E. coli), GST-lacking, full-length
CUP9 bearing the N-terminal “polyoma” (py) epitope tag that
could be detected with a monoclonal antibody (61) (AK6967; a
gift fromDr. S. Stevens andDr. J. Abelson (Caltech)). 0.25ml of
fUBR1-containing yeast extract (5 mg/ml total protein) was
incubated with 15l of anti-FLAGM2 affinity beads (Sigma) at
4 °C for 1 h. The beads were then washed with 1 ml of lysis
buffer (0.2 M KCl, 50 mM HEPES, pH 7.5, 10% glycerol, 0.05%
Nonidet P-40), twice with 1 ml of lysis buffer containing 0.6 M
KCl, once with 1ml of lysis buffer, and twice with 0.5ml of GST
pulldown buffer (see above). The washed beads were incubated
in 0.2ml of GST pulldown buffer at 4 °C for 1 h with 2 or 4l of
purified pyCUP9his6 (0.8 mg/ml), either alone or in the pres-
ence of fUBR1-lacking yeast extract (60 l; 5 mg/ml total pro-
tein). Some of assay samples also contained Arg-Ala and Leu-
Ala dipeptides, at 1 mM each (Sigma). In addition, all assay
samples contained 0.1 mg/ml ovalbumin, a protease inhibitor
mixture (Sigma) and 50 M bestatin (Sigma). Incubated sam-
ples were processed by washing anti-FLAG affinity beads twice
with 0.2 ml of GST pulldown buffer (containing dipeptides at
the same concentrations as in incubated samples), and the
bound proteins were eluted with 0.5 mg/ml FLAG peptide in
GST pulldown buffer, followed by SDS-10% PAGE and immu-
noblotting with antibody to the Py epitope.
X-Peptide Pulldown Assays—Procedures were similar to
those described previously (8, 29, 31, 32). Residues 2–9 of syn-
thetic 12-mer X-peptides (X-Ile-Phe-Ser-Thr-Asp-Thr-Gly-
Pro-Gly-Gly-Cys, where X  Arg, Phe, or Gly), were derived
from residues 2–9 of Sindbis virus polymerase nsP4, a previ-
ously identified N-end rule substrate (1, 62). Hence the acro-
nym for a specificX-peptide, “X-nsP4pep.” 20l (5mg/ml total
protein) of S. cerevisiae extract containing (overexpressed) S.
cerevisiae UBR1 or its fragments (indicated above) was diluted
into 0.2ml of binding buffer (10% glycerol, 0.05%Nonidet P-40,
0.2 M KCl, 50 mM HEPES, pH 7.5) in the presence of 0.1 mg/ml
ovalbumin, protease inhibitor mixture (Sigma), and 50 M
bestatin. The samples were incubated with 5 l (packed vol-
ume) of a carrier-linked X-nsP4pep for 1 h at 4 °C. The beads
were pelleted by a brief centrifugation and thenwashedwith 0.3
ml of binding buffer three times. The beads were then resus-
pended in 30l of SDS-PAGE sample buffer andheated at 95 °C
for 4 min, followed by a brief centrifugation in a microcentri-
fuge, SDS-10% PAGE of 3-l samples of supernatants, and
detection of FLAG-tagged UBR1 or its fragments by immuno-
blotting with anti-FLAGM2 antibody.
Labeling, Purification, and Analysis of X-Peptides—The
above peptides were also employed as probes in the fluores-
cence polarization (FP) assay. To conjugate Alexa Fluor-
488-C5 maleimide (Invitrogen) to C-terminal Cys of an
X-nsP4pep, this dye (0.6 mol in 90 l of dimethyl sulfoxide
(DMSO)) was added to 0.4 mol of X-nsP4pep in 90 l of
DMSO, followed by incubation at room temperature for 4 h.
Alexa-labeled X-peptides were purified by HPLC, using analyt-
ical scale VYDAC column (C18 reverse phase), followed by ver-
ification of purified peptides by mass spectrometry. The con-
centration of labeled X-peptides was measured by using either
BCA reagent (Pierce) or N-terminal sequencing by Edman deg-
radation, or amino acid analysis, with similar results.
Fluorescence Polarization Assay—The concentration of fluo-
rescently labeled X-peptides was kept at 10 nM. Before carrying
out the FP assay, we ascertained that the levels of background
fluorescence of the binding buffer (10% glycerol, 0.02%Nonidet
P-40, 0.2 M KCl, 50 mM HEPES, pH 7.1), of the competitor
(unlabeled) dipeptides or X-peptides, and of the UBR11–1140f
protein (in the same buffer), at their highest concentrations
used, were low enough, less than 5% of the fluorescence of a
labeled X-nsP4pep in the assay. The FP assay (63, 64) was car-
ried out as described in the published protocol (“Fluorescence
Polarization: Technical Resource Guide” (PanVera Corp., now
a part of Invitrogen)), with the followingmodifications. Purified
UBR11–1140f was serially diluted into14 microcentrifuge tubes,
covering the range of its concentrations from more than 10-fold
below(estimated)dissociationconstant (Kd)ofUBR11–1140f inter-
actions with a cognate peptide to more than 10-fold above
estimated Kd. Identical samples of an Alexa-labeled
X-nsP4pep were added to each of the above tubes, gently
mixed, and incubated at 4 °C for 30 min, in the final volume of
50 l. FP measurements were carried out using the Analyst
AD&HT Assay Detection System (Molecular Devices, Sunny-
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vale, CA) and a xenon-arc lamp as a light source, in a standard
FP configuration, with filter settings optimized for the excita-
tion wavelength of 485 nm and the emission wavelength of 530
nm. Two fluorescence measurements were collected for each
well, with either parallel (S and S) or perpendicular (S and P)
polarizers. These data were used to calculate polarization, in
millipolarization units (mP), by the Analyst System. The affin-
ities, expressed as Kd values, were calculated from the above
data. Their statistical significance was estimated by nonlinear
regression analysis, using Prism (Graphpad, San Diego, CA).
FP-based competition assays were carried out similarly, except
that concentration of UBR11–1140f was kept constant, and
(unlabeled) competitor X-peptides were added to the binding
assay. The concentration of UBR11–1140f in competition FP
assays was close to the Kd value (1 M; see “Results”) of the
UBR11–1140f interaction with Arg-nsP4pep.
Surface Plasmon Resonance BIAcore Assay—The X-peptides
Phe-nsP4pep, Arg-nsP4pep, or Gly-nsP4pep were linked,
through their C-terminal Cys (see above), to biotin, using EZ-
Link PEO-Iodoacetyl Biotin (Pierce), to allow immobilization
of peptides onto streptavidin-coated SA sensor chips of BIA-
core-2000 (Biacore). Biotin-labeledX-peptideswere purified by
HPLC, using analytical scale VYDAC column (C18 reverse
phase), followed by verification of purified peptides by matrix-
assisted laser desorption ionization time-of-flight. The concen-
tration of labeled X-peptides was measured using EZTM-Biotin
quantification kit (Pierce). A biotin-containing X-peptide, at
0.1M in the running buffer (0.02%Nonidet P-40, 0.2 MKCl, 50
mMHEPES, pH7.5), was injected over the sensor chip surface at
10 l min1 at 25 °C, resulting in the surface density for the
X-peptide of 30–35 resonance units. Purified UBR11–1140f was
serially diluted in running buffer and injected at 75l min1 for
80 s at 25 °C. After 5 min, to allow dissociation of the formed
complexes, the sensor chip was washed by two 1-min injections
of 2 MMgCl2 at 50l/min. BIAcore readouts were corrected by
subtracting readouts from the mock surface (lacking an X-pep-
tide) as well as readouts from a buffer-only (control) injection.
Raw data were processed using Scrubber (BioLogic Software,
Australia) and CLAMP programs and the 1:1 Langmuir inter-
action model, with a correction for mass transport (65, 66).
UBR1-dependent in VitroUbiquitylation System—This com-
pletely defined system, consisting exclusively of purified
recombinant proteins and small compounds, was described in
Ref. 40 and in detail in Ref. 67. Briefly, C-terminallyHis6-tagged
S. cerevisiae UBA1 (E1, Ub-activating enzyme) was overex-
pressed in S. cerevisiae SC295 and purified using nickel-nitrilo-
triacetic acid (His6 affinity) chromatography, immobilized Ub
(“covalent” affinity) chromatography, and Superdex-200 gel fil-
tration (68). S. cerevisiae RAD6 (UBC2) was overexpressed in
E. coli and purified by fractionation over DEAE, Mono-Q, and
Superdex-75 columns. N-terminally FLAG-tagged S. cerevisiae
UBR1 (fUBR1) was overexpressed in S. cerevisiae, as described
section above, and was purified by fractionation over immobi-
lized anti-FLAGM2 antibody, immobilized RAD6, and Super-
dex-200 columns (Fig. 7D). N-terminally FLAG-tagged, C-ter-
minally His6-tagged S. cerevisiae fCUP9his6 was expressed and
labeled with [35S]methionine in E. coli, followed by purification
over nickel-nitrilotriacetic acid and anti-FLAG M2 antibody
columns. Details of these and related procedures are described
in Ref. 67. We also employed a similarly produced, labeled, and
purified pyCUP9his6 with a different N-terminal tag, called
polyoma (py) that was bound by a monoclonal antibody (61)
(AK6967; a gift from Dr. S. Stevens and Dr. J. Abelson
(Caltech)). The in vitro ubiquitylation reactions contained the
following components: 7 MUb, 50 nM UBA1, 50 nM RAD6, 50
nM UBR1, 550 nM 35S-labeled fCUP9his6, 25 mM KCl, 5 mM
MgCl2, 2 mM ATP, 0.1 mM dithiothreitol, 25 mM HEPES, pH
7.5, and ovalbumin (as a carrier protein) at 0.5 mg/ml. Pairs of
dipeptides were added to final concentrations specified in the
legend to Fig. 8. All components except UBA1 were mixed on
ice for 10 min; UBA1 was then added and reactions shifted to
30 °C. The reactions were carried out for 10 min and were ter-
minated by adding an equal volume of 2 SDS-PAGE loading
buffer and heating at 95 °C for 5 min, followed by SDS-10%
PAGE and autoradiography.
Genetic Screen for Type-1 and Type-2 UBR1 Mutants—Fig.
1B describes the design of the screen. Reporter plasmids
expressing either Arg-URA3 (a type-1 N-end rule substrate)
and Leu-gal (a type-2 N-end rule substrate) (pDSRULB plas-
mid) or Leu-URA3 (a type-2 substrate) and Arg-gal (a type-1
substrate) (pDSLURBplasmid) were transformed into S. cerevi-
siae JD55, a ubr1 strain. pRBUBR1, a high copy plasmid
expressing UBR1 from the PADH1 promoter, was mutagenized
by treatment with 1 M hydroxylamine for 1 h at 75 °C. DNAwas
precipitated with ethanol, redissolved in 1 mM EDTA, 10 mM
Tris-HCl, pH 8.0, and hydroxylamine was removed using G-25
spin-desalting column (Roche Applied Science). Hydroxyla-
mine-treated pRBUBR1 was transformed into JD55 (ubr1)
carrying one of two reporter plasmids, either pDSRULB or
pDSLURB. The transformants were plated onto SD(Ura)
plates, and the resultingUra colonies (cells thatwere, presum-
ably, impaired in degrading either Arg-URA3 or Leu-URA3)
were replica-plated onto galactose-containing SG plates. The
colonies on SG plates were stained for gal using XGal overlay.
Most of the colonies in these experiments stained blue. Because
the cells of these colonies were selected, in the preceding step,
to be impaired in the degradation of one class (type-1 or type-2)
of N-end rule substrates, the failure to degrade an X-gal that
belonged to the other class of N-end rule substrates (type-2 or
type-1, respectively) meant that the corresponding alleles of
UBR1 were defective in degrading both classes of N-end rule
substrates However, some white colonies on XGal were pro-
duced as well, with each of the two bi-reporter plasmids,
pDSRULB and pDSLURB. The corresponding pRBUBR1
plasmids were rescued from these white colonies and were
retransformed into the JD55 (ubr1) cells carrying other
reporter plasmids, either pBAM (Met-URA3), or pBAR
(Arg-URA3), or pBAL (Leu-URA3). The resulting transfor-
mants were plated onto either SD (Ura) or SD(Ura) to
verify that the corresponding variants of UBR1 were indeed
selectively impaired in the degradation of either type-1 or
type-2 N-end rule substrates.
Mapping Type-1/2Mutations in UBR1—Five fragments of S.
cerevisiae UBR1, from the pRB208 plasmid, were produced
using the following restriction endonucleases: fragment I,
SmaI-SpeI (nt 1–510 of theUBR1ORF); fragment II, SpeI-BglII
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(nt 510–1,653); fragment III, BglII-BalI (nt 1,653–3,511); frag-
ment IV, BalI-XbaI (nt 3,511–4,515); and fragment V, XbaI-
PstI (nt 4,515-beyond the end of ORF). Each of these fragments
was replaced, in the non-mutant pRBUBR1, by the correspond-
ing fragments from a rescued and amplified mutant pRB208,
yielding five pRBUBR1-derived plasmids for everymutant plas-
mid. The five plasmids were transformed, separately, into JD55
(ubr1) cells carrying either pBAR (Arg-URA3) or pBAL (Leu-
URA3), and the transformants were tested for their ability to
grow in the absence of uracil. This waywe identified the regions
of relevant alterations in the UBR1 ORF. The corresponding
fragments were then sequenced to identify the actual
alteration(s).
Pulse-Chase Analysis—S. cerevisiae in liquid SD medium
containing 0.1mMCuSO4 (A600 0.5–1)were labeled for 2min at
30 °C with 0.15 mCi of [35S]methionine/cysteine (EXPRESS,
PerkinElmer Life Sciences) as described (21, 52). Cells were
harvested by centrifugation, resuspended in 0.3 ml of SD
medium containing 10 mM L-methionine and 0.5 mg/ml cyclo-
heximide, and incubated further at 30 °C. Samples of 0.1 ml
were removed during the incubation and added to microcen-
trifuge tubes containing 0.5ml of 0.5-mmglass beads and 0.7ml
of lysis buffer (1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 50
mM Na-HEPES, pH 7.5, and 1 protease inhibitor mixture
(Sigma)). The cells were lysed by vortexing with glass beads,
followed by immunoprecipitation with anti-ha antibody
(Covance, Princeton, NJ), SDS-PAGE, autoradiography, and
quantitation (21, 56). Immunoprecipitation of labeled CUP9-
FLAG was carried out as described (39).
-Galactosidase and Other Assays—Cells in 5-ml cultures
(A600 0.8–1) were pelleted by centrifugation at 12,000 g for 2
min and lysedwith glass beads in 20%glycerol, 1mMdithiothre-
itol, 0.1 MTris-HCl, pH 8, and the activity ofgal wasmeasured
in the clarified extract using o-nitrophenyl--D-galactoside, as
described (50, 69). The activity was normalized to the total pro-
tein concentration, determined using Bradford assay (Bio-Rad).
For growth-dilution assays, S. cerevisiae strains were grown
under selection for plasmids in SDmedium to anA600 of 0.8–1.
Cells (1.5 107) from each sample were pelleted by centrifuga-
tion and resuspended in 1ml of water. 4-Fold serial dilutions of
cell cultures were set up in microtiter plates as described (39),
and cell suspensions were transferred to various media using a
48-pin applicator, followed by incubation at 30 °C for36 h to
assay for growth.
RESULTS
UBR1 Mutants That Are Selectively Defective in Targeting
Type-1 or Type-2 N-end Rule Substrates—To locate the regions
of S. cerevisiaeUBR1 that encompass its type-1 and type-2 sub-
strate-binding sites (see Introduction), and to determine
whether these apparently distinct sites (1, 28, 69) are suffi-
ciently modular (independent) to be selectively perturbed by
mutations, we carried out a screen described in Fig. 1B and
“Experimental Procedures.” A plasmid that expressed Arg-
URA3 (a type-1 N-end rule substrate) and Leu-gal (a type-2
N-end rule substrate), or an otherwise identical plasmid that
expressed a “converse” set of reporters, Leu-URA3 (a type-2
substrate) and Arg-gal (a type-1 substrate), were transformed
into ubr1 S. cerevisiae, which lacked the N-end rule pathway.
pRBUBR1, a high copy plasmid expressing UBR1, was
mutagenized in vitrowith hydroxylamine and transformed into
FIGURE 1. TheN-end rule pathway in the yeast S. cerevisiae. A, S. cerevisiae
N-end rule pathway. N-terminal residues are indicated by single-letter abbre-
viations for amino acids. Yellow ovals denote the rest of a protein substrate.
Hemin (Fe3-heme)hasbeen found to inhibit thearginylationactivity of both
the S. cerevisiae and mouse ATE1-encoded Arg-tRNA-protein transferase
(R-transferase) (4). At least in mammalian cells, hemin also induces the
proteasome-dependent degradation of R-transferase (4). MetAPs, methio-
nine aminopeptidases. Separase refers to the ESP1-encoded protease that
cleaves, in particular, the SCC1 subunit of cohesin and thereby allowsmitosis
(86). The resulting C-terminal fragment of SCC1bears a destabilizingN-termi-
nal residue (Arg in S. cerevisiae) and is degraded by the N-end rule pathway, a
step that is essential for high fidelity of chromosome segregation (43). The
reactions in a shaded rectangle are a part of the N-end rule pathway that is
active in eukaryotes (e.g. vertebrates) that produce nitric oxide (NO) (6), but is
also relevant to organisms such as S. cerevisiae, which lack NO synthases but
can produce NO by other routes, and in addition can be influenced by NO
from extracellular sources. C* denotes oxidized Cys, either Cys-sulfinate or
Cys-sulfonate, produced in reactions mediated by nitric oxide, oxygen, and
their derivatives. Oxidized N-terminal Cys is arginylated by ATE1-encoded
isoformsof R-transferase (6, 7). Type-1 and type-2primary destabilizingN-ter-
minal residues (see Introduction) are recognized by UBR1, the sole N-recog-
ninof S. cerevisiae that functions as aholoenzymecontainingUBR1and theE2
enzyme RAD6. Through its third substrate-binding site, UBR1 recognizes
internal (non-N-terminal) degrons in substrates (denoted by a larger oval)
such as CUP9, a transcriptional repressor of regulon that includes the PTR2
peptide transporter (8, 39, 40). The addition of hemin to S. cerevisiae UBR1 in
vitro (in cell extracts) was found to inhibit the interaction of UBR1 (through its
third substrate-binding site) with CUP9 (4). This inhibition was selective in
that hemin did not interfere with the binding of primary destabilizing N-ter-
minal residues of peptide reporters to the type-1 or type-2 binding sites of
UBR1 (4). B, design of a genetic screen to isolate UBR1 mutants with selec-
tively inactivated type-1 or type-2 substrate-binding sites. C, locations of
mutations in S. cerevisiaeUBR1 thatwere found to selectively inactivate either
the type-1 siteor the type-2 site. Themutant residues are in red.For thenames
of specific UBR1 domains, see Refs. 9, 29, 32 and the main text.
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ubr1 cells carrying one or the other of the double-reporter
plasmids (Fig. 1B). By replica-plating transformants on uracil-
lacking SD plates, we could identify cells in which an X-URA3
reporter remained long lived in the presence of pRBUBR1 from
the mutagenized pool, as those cells were Ura, because of
higher steady-state levels of URA3. (Both Arg-URA3 and Leu-
URA3were long lived in ubr1 cells but short lived inwild-type
cells (1, 70).) Ura colonies were then plated on galactose-con-
taining SG plates. The levels of galactose-induced Arg-gal (in
the Leu-URA3-expressing plasmid) or Leu-gal (in the Arg-
URA3-expressing plasmid) could then be assessed by staining
the colonies with XGal. A blue, i.e. high-gal colony (which
already proved to be Ura at the preceding step of the screen),
would imply the presence of aUBR1 allele that was impaired in
degradation of both type-1 and type-2 substrates (Fig. 1B).Most
colonies in these experiments stained blue. The rare white col-
onies on XGal suggested the presence of UBR1 variants selec-
tively impaired in one but not the other of two substrate-bind-
ing sites. The pRBUBR1 plasmids were rescued from these
colonies and were retransformed into ubr1 cells carrying
either Met-URA3 (not an N-end rule substrate and a relatively
long lived protein), or Arg-URA3 (type-1 substrate), or Leu-
URA3 (type-2 substrate). Plating transformants on either SD
(Ura) or SD (Ura) plates could verify whether the corre-
sponding variants ofUBR1were selectively impaired in the deg-
radation of type-1 or type-2 N-end rule substrates (Fig. 1B).
The initial screen involved 2,000 transformants bearing
mutagenizedUBR1.With each of two reporter plasmids,10%
of these transformants were Ura. Among these, noUBR1 iso-
lates were found that were unable to confer instability on a
type-1 N-end rule substrate (basic N-terminal residues) but
retained the activity against a type-2 substrate (hydrophobic
N-terminal residues). However, this screen did yield five puta-
tive UBR1 variants of the opposite kind (active against type-1
but not type-2N-end rule substrates). Amore extensive screen,
with1 106 transformants, was then carried out exclusively
for UBR1 variants of the former class (active against type-2 but
not type-1 substrates). It yielded 17,000 Ura colonies, i.e.
isolates in which Arg-URA3 was at least partially stabilized. 20
of these colonies showed low levels ofgal in theXGal assay (i.e.
they retained degradation of Leu-gal). The pRBUBR1 plas-
mids encoding 20putative type-1-impaired and 5putative type-
2-impaired UBR1 variants were rescued, and the specificity of
their targeting defects was confirmed by re-testing them in
ubr1 cells expressing either Arg-URA3 and Leu-gal or Leu-
URA3 and Arg-gal, using, in particular, pulse-chase and
immunoblot assays (data not shown; see also below).
Identifying Mutations in UBR1—The approximate locations
of mutations within the 5,850-bp UBR1 ORF were determined
through fragment swapping between wild-type and mutant
UBR1s, using unique restriction sites to divide UBR1 into five
nonoverlapping fragments (see “Experimental Procedures”).
Once localized to a specific fragment, the actual mutation was
determined by DNA sequencing. All of the type-1 and type-2
mutationswere located in theN-terminal 30%ofUBR1.Among
20 type-1 mutant isolates of UBR1 (those active with type-2
substrates but inactive with type-1 substrates), only 5 different
amino acid changes were present, with 18 of the 20 mutations
affecting either Asp176 or Gly172 (Fig. 1C). All of recovered
type-1 mutations in UBR1 were missense alterations, one of
them a double missense, in two adjacent residues. Specific
changes in the type-1 UBR1 mutants were C145Y/V146M (a
double missense; one isolate); G172R (seven isolates); G172E
(four isolates); D176N (five isolates); and D176E (two isolates),
encompassing an30-residue region of UBR1 (positions 145–
176) (Fig. 1C). In contrast to type-1UBR1mutants, all five of the
type-2 UBR1 mutants contained different amino acid alter-
ations; collectively, these (type-2) alterations encompassed a
different and larger region of UBR1 (positions 313–560). Spe-
cific type-2 alterations were V313I; D318N; H321Y; P406S; and
E560K (Fig. 1C). Together, the identified type-1 and type-2
mutations spanned a 416-residue stretch within the first 560
residues of the 1,950-residue UBR1 protein.
Degradation of N-end Rule Substrates in Type-1 or Type-2
UBR1 Mutants—Specific type-1 and type-2 S. cerevisiae UBR1
mutants were verified and further characterized by transform-
ing the corresponding UBR1-expressing plasmids into JD55
(ubr1) S. cerevisiae carrying pRgalUPR or pLgalUPR. The
latter are low copy plasmids expressing, respectively, Arg-gal
or Leu-gal reporterN-end rule substrates. The relative rates of
in vivo degradation of X-gals were assessed using extensively
validated (9, 24) steady-state measurements of gal activity in
whole cell extracts from ubr1 cells that carried plasmids
expressing specific UBR1mutants (Fig. 2, A and B). The results
confirmed the initial screen-derived data that Arg-gal was
long lived in the presence of type-1 UBR1 mutants, but was de-
graded with type-2 UBR1 mutants. Conversely, Leu-gal was
long lived in the presence of type-2 UBR1 mutants but short
lived with type-1UBR1mutants (Fig. 2,A and B). In addition to
steady-state levels of N-end rule substrates (Fig. 2, A and B),
their metabolic stability was also assessed by pulse-chase anal-
ysis, using the Ub-protein-reference (UPR) technique (21, 57).
Thismethod provides a “built-in” (long lived) reference protein
as a part of reporter fusion, and thereby increases the accuracy
of pulse-chase and analogous assays. In agreement with steady-
state data (Fig. 2, A and B), Arg-URA3 was relatively long lived
in type-1 UBR1mutants, exemplified byUBR1D176E-1 cells (the
superscript suffixes “-1” or “-2” denote the inactivation of,
respectively, the type-1 or type-2 substrate-binding sites of
UBR1). In contrast, Leu-URA3 was short lived in a type-1
mutant (Fig. 2D and data not shown; see also Fig. 1C). “Con-
versely,” Leu-URA3 was relatively long lived in type-2 UBR1
mutants, exemplified by UBR1P406S-2, whereas Arg-URA3 was
short lived in the samemutant (Fig. 2D and data not shown; see
also Fig. 1C). (Both Arg-URA3 and Leu-URA3 were long lived
in the absence of UBR1 (Fig. 2C).)
UBR1-dependent Targeting of CUP9 Requires Intact Type-2
Binding Site ofUBR1—Previouswork has shown that theN-end
rule pathway controls the import of short peptides (8, 39–41).
Specifically, a third substrate-binding site of S. cerevisiaeUBR1,
apparently distinct from its two other (type-1 and type-2) bind-
ing sites, targets CUP9. The latter is a transcriptional repressor
of, among other genes, PTR2, which encodes a plasma-mem-
brane transporter that can import di- and tripeptides. UBR1
targets CUP9 for ubiquitylation and subsequent degradation
through a distinct internal (non-N-terminal) degron of CUP9.
UBR1 Ubiquitin Ligase
AUGUST 29, 2008•VOLUME 283•NUMBER 35 JOURNAL OF BIOLOGICAL CHEMISTRY 24017
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on August 22, 2008 
w
w
w
.jbc.org
D
ow
nloaded from
 
In wild-type cells, peptides with destabilizing N-terminal resi-
dues bind to the type-1 and type-2 binding sites of UBR1 and
thereby allosterically activate its otherwise autoinhibited third
site for binding to CUP9 (8, 40). This reversal of autoinhibition
leads to the targeting of CUP9 by UBR1, to accelerated degra-
dation of CUP9, and thus to the induction of PTR2 expression
and peptide import. The resulting positive feedback circuit
allows S. cerevisiae to detect the
presence of extracellular peptides
and to react by increasing their
uptake (8, 40). In ubr1 yeast, CUP9
is a relatively long lived protein (t1⁄2
50 min). As a result, the expres-
sion of PTR2 transporter is extin-
guished,making ubr1 cells incapa-
ble of importing peptides and
therefore resistant to a toxic dipep-
tide such as Leu-Eth (39).
We employed the toxic peptide
resistance assay to probe in vivo
aspects of UBR1 mutants identified
in this study work. Plasmids
expressing type-1 or type-2 mutant
alleles of UBR1 were transformed
into ubr1 yeast, and the resulting
transformants were streaked onto
Leu-Eth (toxic peptide) plates.
Growth of cells on such plates indi-
cates that the CUP9 repressor is
metabolically stabilized in these
cells, resulting in a down-regulation
of expression of PTR2 transporter
and therefore in hyper-resistance of
cells to Leu-Eth. The results showed
that CUP9 was stabilized in cells
transformedwith all of type-2UBR1
mutants (Fig. 3B), but it was still
degraded in cells transformed with
four of the five type-1 UBR1
mutants (Fig. 3A). (With the fifth
type-1 mutant, UBR1CV145YM-1
(Fig. 1C), cell growth on Leu-Eth
plates was partially retarded relative
to ubr1 strains.) These findings
suggest that the third (CUP9-recognizing) site of UBR1 either
structurally overlaps with the type-2 binding site or depends on
this site for its function.
Specificity of UBR1 Interactions with N-end Rule Substrates
and X-Peptides—Our previous work described the use of
N-recognin ligands containing the GST moiety linked to the C
terminus of a fragment of S. cerevisiae SCC1, a subunit of cohe-
sin. This 33-kDa SCC1 fragment, which normally bears N-ter-
minal Arg, is produced in yeast through the conditional cleav-
age by separase ESP1 and is degraded by the N-end rule
pathway (43). Purified X-SCC1-GSTs (X  Arg, Leu, or Met)
bearing type-1 (Arg), or type-2 (Leu), or stabilizing (Met)N-ter-
minal residues were linked to glutathione-Sepharose, and the
previously characterized (8) GST pulldown assay was carried
out with yeast extracts that contained the overexpressed,
FLAG-tagged, full-length fUBR1 or its derivatives (Fig. 4). Sim-
ilarly to mouse UBR1 and UBR2 (31), S. cerevisiae fUBR1 did
not bind toMet-SCC1-GST (Fig. 4D, lane 1) but bound to both
Leu-SCC1-GST and Arg-SCC1-GST (Fig. 4, A and B, lanes 2).
This binding was specific for type-1 versus type-2 N-terminal
residues, as the Arg-Ala and Leu-Ala dipeptides selectively
FIGURE 2.Selective inactivationof type-1 versus type-2 substrate-binding sites inUBR1mutants.A, wild-
type UBR1 and itsmutant alleles were expressed from low copy plasmids in S. cerevisiae JD55 (ubr1) cells that
also carried a plasmid expressing Arg-gal (Ub-Arg-gal) reporter (see “Experimental Procedures”). Measure-
ments of gal activity in cell extracts were used to compare the rates of X-gal reporter degradation in vivo (9,
21). The values shown are the means of duplicate measurements of three independent transformants. Stand-
ard deviations are indicated above the bars. For the locations of indicated mutations in UBR1, see Fig. 1C.
B, same as in A but with cells expressing Leu-gal (Ub-Leu-gal). C, pulse-chase assays, using a UPR-type
construct (21, 57) expressing either Met-URA3ha, or Arg-URA3ha, or Leu-URA3ha in ubr1 cells (see “Experi-
mental Procedures”). Lane 1,molecular mass marker; their masses, in kDa, are indicated on the left.D, same as
in C, but with ubr1 cells that expressed either wild-type UBR1, or its type-1 UBR1D176E-1 mutant, or its type-2
UBR1P406S-2 mutant. The 35S-bands of X-URA3ha reporters and the DHFRh-Ub reference protein are indicated.
FIGURE 3. In vivo effects of mutants in the type-1 or type-2 substrate-
binding sites of UBR1. A, toxic-peptide (Leu-Eth) resistance assay (39, 41)
(see “Experimental Procedures”) with ubr1 S. cerevisiae versus its derivatives
that expressed type-1 UBR1 mutants (Fig. 1C). B, same as in A, but the assay
was carried with type-2 UBR1 mutants, and the result with wild-type UBR1 is
shown as well (Fig. 1C). See the main text for details.
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inhibited the binding of corresponding (“alternative”) X-SCC-
GST reporters (Fig. 4, A and B). To probe specificity of this
inhibition, we tested other small compounds as well. Whereas
increasing concentrations of Arg-Ala inhibited the binding of
Arg-SCC1-GST to fUBR1, neither Ala-Arg, nor an equimolar
mixture of the corresponding free amino acids (ArgAla), nor
Arg methyl ester (Arg-OMe), nor agmatine ((4-aminobutyl)-
guanidine), the decarboxylation product of Arg and a putative
neurotransmitter (71)) exhibited this effect (Fig. 4, A and C).
Similarly, the binding of Leu-SCC1-GST to fUBR1 was inhib-
ited by Leu-Ala but neither byArg-Ala (31), nor byAla-Leu, nor
by LeuAla (a mixture of free amino acids) (Fig. 4D).
In agreementwith earlier findings (8), both full-length fUBR1
and UBR11–1140f (N-terminal “half” of fUBR1) exhibited quali-
tatively indistinguishable patterns of binding specificity (Fig. 4,
E and F), indicating that UBR11–1140f contained the type-1 and
type-2 binding sites. It should be noted that whereas Arg-OMe
(in contrast to Arg-Ala) did not inhibit the binding of Arg-
SCC1-GST to either UBR11–1140f or full-length fUBR1, the
analogous methyl ester Leu-OMe inhibited the binding of Leu-
SCC1-GST apparently as efficaciously as did Leu-Ala (Fig. 4,
C–F). Yet another difference between the inhibition patterns of
type-1 and type-2 sites was a comparably strong inhibition, by
either Leu-Ala or Leu-Asp, of the binding of Leu-SCC1-GST to
UBR1 versus the absence of inhibition, by Arg-Asp (in contrast
to Arg-Ala), of the binding of Arg-SCC1-GST to UBR1 (Fig. 4,
C–F). Detailed understanding of these differences requires the
knowledge of the crystal structure of UBR1.
The binding of UBR1 to destabilizing N-terminal residues of
polypeptides was also examined using the X-peptide assay,
which employed a set of otherwise identical 12-mer peptides
(termed X-nsP4pep) whose sequence X-Ile-Phe-Ser-Thr-Asp-
Thr-Gly-Pro-Gly-Gly-Cys (X  Arg or Phe) was derived, in
part, from theN-terminal sequence of nsP4, the RNA polymer-
ase of the Sindbis virus and a physiological N-end rule substrate
(27, 62). Purified X-nsP4pep peptides were cross-linked to
microbeads through their C-terminal Cys residue (8, 31, 32).
Both full-length fUBR1 and several of its truncated deriva-
tives were overexpressed in S. cerevisiae and assayed for their
binding to either Arg-nsP4pep or Phe-X-nsP4pep. Whereas
fUBR11–717, the 717-residue N-terminal fragment of the
1,950-residue UBR1, was capable of specific binding to
X-nsP4pep peptides, shorter N-terminal fragments of UBR1
did not bind (Fig. 4, G and H). In addition, UBR1209–1140f,
which differed from the binding-competent UBR11–1140f by
deletion of the first 208 residues, did not bind to either Arg-
nsP4pep or Phe-X-nsP4pep (Fig. 4, G, H and J). All of these
findings were consistent with the conclusions from genetic
mapping of the type-1 and type-2 sites (Fig. 1C).
Measurements of Affinity between UBR1 and Peptide Report-
ers Using Fluorescence Polarization Assay—To measure the
binding of UBR1 to different N-terminal residues of otherwise
identical polypeptides, we employed both fluorescence polar-
ization (FP) (63, 64, 66) and surface plasmon resonance (SPR)
(72, 73). These measurements used purified UBR11–1140f (Fig.
4I). Its specific binding toN-terminal residues of either protein-
size substrates or short peptides was indistinguishable from
that of full-length fUBR1 in GST pulldown assays (Fig. 4, A–F).
The otherwise identical Arg-nsP4pep, Phe-nsP4pep, and Gly-
nsP4pep peptides, with type-1 destabilizing, type-2 destabiliz-
ing, and stabilizing N-terminal residues, respectively (Fig. 1A),
were C-terminally conjugated to Alexa Fluor-488, followed by
purification of the resulting fluorescent peptides by HPLC and
verification of their structures by mass spectrometry (see
“Experimental Procedures”).
The concentration of X-nsP4pep (C-terminal symbol
denotes fluorescent tag) in FP assays was set at 10 nM, well
below the (anticipated) micromolar range of affinities between
UBR1 and test peptides. As expected (8), both Arg-nsP4pep
and Phe-nsP4pep interacted with UBR11–1140f. The calcu-
latedKd values (see “Experimental Procedures”) were1.0 and
0.7 M, respectively. In contrast, no binding to UBR11–1140f
could be detected with the otherwise identical Gly-nsP4pep,
i.e. the correspondingKdwas at least 0.1mM or higher (Fig. 5,A
and B). The affinities of X-nsP4pep peptides for UBR11–1140f
were also measured in a competition FP assay, in which, for
example, the binding of Phe-nsP4pep to UBR11–1140f was
titrated by the addition of Alexa lacking (unlabeled) Phe-
nsP4pep (Fig. 5F). The corresponding Kd was 2 M, close to
the value deduced fromdirect binding FP assay (Fig. 5,B and F).
In contrast, the competition by unlabeled Arg-nsP4pep (a
type-1 destabilizing N-terminal residue) or by unlabeled Gly-
nsP4pep (a stabilizing N-terminal residue) for the binding of
Phe-nsP4pep to UBR11–1140f was too weak to measure by
FP (Fig. 5F). The Kd value of Arg-nsP4pep binding to
UBR11–1140f that was deduced from a similar competition
assay, using unlabeled Arg-nsP4pep as a competitor, was
1.2 M, close to the value of 1.0 M from direct-binding
assay (Fig. 5, A and C). Interestingly, however, the unlabeled
Phe-nsP4pep could detectably compete with the binding of
(labeled) Arg-nsP4pep to UBR11–1140f (Fig. 5C), with the appar-
entKdof11M, i.e.Phe-nsP4pepwasan10-foldweaker inhib-
itor of the binding of Arg-nsP4pep to UBR11–1140f than Arg-
nsP4pep itself. As to unlabeled Gly-nsP4pep, its apparent
binding to the type-1 site of UBR11–1140f was weaker still but
could still be detected in this competition assay, with the cor-
responding (apparent) Kd of36 M (Fig. 5C).
We conclude that the type-1 and type-2 substrate-binding
sites of UBR1 bind to the correspondingN-terminal residues of
model substrates with approximately equal affinities (Kd of1
M). We also conclude that the UBR1 type-2 site, which binds
to bulky hydrophobic N-terminal residues (Fig. 1A), is signifi-
cantlymore discriminating than the type-1 site. Specifically, we
could not detect the binding of noncognate N-terminal resi-
dues to the type-2 site of UBR1, in either qualitative or quanti-
tative assays (Fig. 4 and Fig. 5, B and F), whereas a type-2 N-ter-
minal residue could weakly compete with a type-1 N-terminal
residue for the binding to the type-1 site of UBR1, and a stabi-
lizing N-terminal residue could also compete, albeit even more
weakly than a type-2 residue (Fig. 5, A–F).
We also carried out competition assays with unlabeled
dipeptides and other dipeptide size compounds versus either
Arg-nsP4pep or Phe-nsP4pep (Fig. 5, D, E and G). Some of
these competitors were also used in qualitative binding assays
(Fig. 4, D and E). The results of FP-based competition assays
indicated that dipeptides (as distinguished from 12-mer
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X-nsP4pep peptides) with cognate
N-terminal residues were signifi-
cantly (5–10-fold) weaker competi-
tors relative to unlabeled cognate
X-nsP4pep peptides (Fig. 5, D and
G), and that dipeptides (or analo-
gous compounds) with noncognate
N-terminal residues were either not
competitors at all or much weaker
competitors (see the legend to Fig. 5,
D and G for details). Among the
tested dipeptide sequences, Ala at
position 2 of an otherwise cognate
dipeptide (Arg-X or Leu-X) resulted
in best competitor dipeptides,
whereas a negatively charged
(Asp) residue at position 2 signifi-
cantly decreased the affinity of a
dipeptide for the corresponding
(type-1 or type-2) substrate-bind-
ing site of UBR1 (Fig. 5, D and G).
A basic (Arg or Lys) residue at
position 2 was not as detrimental
for the interaction of dipeptide
with UBR1 (Fig. 5, D and G).
Although the length of a compet-
itor peptide is less important than
whether or not it bears a cognate
N-terminal residue, the data of Fig.
5,H and I, indicate that the length of
a peptide (in the tested range) is a
significant, apparently independent
parameter that determines its affin-
ity for UBR1. One possibility is that
the C-terminal carboxyl group of
the peptide (e.g. its negative charge)
would weaken the binding of pep-
tide to its cognate (type-1 or type-2)
binding site of UBR1, unless the
peptide is long enough to place its
C-terminal carboxyl group away
from the binding site. This interpre-
tation would also account for the
fact that free “cognate” amino acids
(in contrast to dipeptides bearing
them asN-terminal residues) do not
bind to UBR1 (Fig. 4, C and E).
Measurements of Affinity between
UBR1 and Model Peptides Using Surface Plasmon Resonance—
To measure the affinity between UBR11–1140f and 12-mer
X-nsP4pep peptides using a technique other than FP (Fig. 5), we
employed SPR and BIAcore-2000 (65, 66, 72, 73). Phe-nsP4pep,
Arg-nsP4pep, or Gly-nsP4pep, modified to bear a C-terminal
biotin moiety (see “Experimental Procedures”), were immobi-
lized on streptavidin-coated sensor chips. Purified UBR11–1140f
(see Fig. 4I) was serially diluted in the running buffer and
injected over the chip surface for 80 s. BIAcore readouts
were corrected by subtracting readouts from the mock
surface (lacking an X-peptide) as well as readouts from buff-
er-only (control) injections. Raw data were processed using
Scrubber (BioLogic Software) and were globally fit using
CLAMP (65), yielding the corresponding Kd values. As
shown in Fig. 6, BIAcore detected the binding of UBR11–1140f
to either Arg-nsP4pep (bearing a type-1 destabilizing N-ter-
minal residue) or Phe-nsP4pep (bearing a type-2 destabiliz-
ing N-terminal residue), with the Kd values of1.2 and1.0
M, respectively (Fig. 6), in excellent agreement with the
results of FP-based measurements (Fig. 5 and see preceding
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section). In contrast, the otherwise identical Gly-nsP4pep,
bearing a stabilizing N-terminal residue, did not exhibit a
detectable binding to UBR11–1140f (Fig. 6C). These BIAcore-
based findings (Fig. 6) demonstrated yet again (in addition to
GST pulldown and FP-based data) that at least the bulk of
the in vivo specificity of UBR1 for N-end rule substrates (Fig.
1, A and B) (see Introduction) stems from differences in its
physical affinity for destabilizing versus stabilizing N-termi-
nal residues in the N-end rule.
Nonspecific Binding of Purified UBR1 to CUP9, and Restora-
tion of Specificity through Chaperones and Macromolecular
Crowding—Through its type-1 and type-2 sites, the 225-kDa
UBR1 can bind to primary destabilizing N-terminal residues in
proteins or short peptides apparently “nonconditionally,” i.e.
under all conditions tested (8) (Figs. 4–6). In contrast, UBR1
can bind, through its third binding site, to its physiological sub-
strate CUP9 only if the type-1 and type-2 sites of UBR1 are
occupied by cognate N-terminal residues of ligands such as
dipeptides (8) (e.g. Fig. 7, E–G, lanes 2 and 3). This dependence
of the UBR1-CUP9 interaction (via the C terminus-proximal
degron of CUP9 (8) (Fig. 7, B and C)) on the state of occupancy
of other two binding sites of UBR1 yields, in vivo, a positive
feedback circuit through which S. cerevisiae can sense the pres-
ence of extracellular peptides and accelerate their uptake (8, 40)
(see Introduction). The negligible binding of CUP9 by UBR1 in
the absence of occupancy of its type-1/2 sites (e.g. Fig. 7, E–G,
lanes 2 and 3) is thus the consequence of a negligible fraction of
UBR1molecules, under these conditions, that exhibit an “open”
(active) CUP9-binding site.
The binding of type-1/2 ligands to the corresponding sites
of UBR1 increases, in an ensemble of UBR1 molecules, the
probability of a conformational transition that “opens up”
the CUP9-binding site of UBR1 (8). The type-1/2 sites of
UBR1 encompass its N-terminal and proximal UBR domain
(Fig. 1C and Introduction). The allosteric influence of UBR1-
bound dipeptides on the probability of transition that
induces the UBR1-CUP9 interaction was shown to require
the evolutionarily conserved C-terminal region of UBR1 that
includes two critical cysteines, Cys1703, and Cys1706 (8). In par-
ticular, UBR11–1140f, the N-terminal “half” of UBR1, retains all
three of its substrate-binding sites but exhibits a constitutively
open (active) CUP9-binding site. More recent findings, using
UBR1 derivatives that contained sequences allowing site-spe-
cific cleavages of UBR1, indicated that a conformational tran-
sition in UBR1 that “opens up” its CUP9-binding site is “subtle”
in that it does not appear to involve a large scale repositioning of
UBR1 domains.4
GST pulldowns with UBR1 versus GST-CUP9 were carried
out in the presence of yeast extract (8) (e.g. Fig. 7, E–G, lanes 2
and 3). We repeated these assays with purified UBR1 (see
“Experimental Procedures”) and GST-CUP9. Surprisingly, the
specificity of UBR1-CUP9 interaction, i.e. its dependence on
the presence of dipeptides with destabilizing N-terminal resi-
dues, as well as its dependence on the presence of C-terminal
degron of CUP9 (67) were abolished with purified UBR1; it
bound to GST-CUP9 irrespective of the presence or absence of
dipeptides and irrespective of the presence or absence of the
UBR1-specific degron of CUP9 (Fig. 7, C and F, and data not
shown). These effects of using purified UBR1 (as distinguished
fromUBR1 in the presence of yeast extract) were also observed
with itsN-terminal fragmentUBR11–1140f (Figs. 4K and 7B). For
example, in the presence of yeast extract, UBR11–1140f bound to
CUP9 constitutively (i.e. independently of the presence of
dipeptides) (8) but specifically (i.e. depending on the presence
of the CUP9 degron) (Fig. 7B). However, purified UBR11–1140f
bound either to full-length CUP9 (containing its C-terminal
degron) or toC-terminally truncatedCUP91–221 that lacked the
degron (Fig. 4K, lanes 1–6). The same pattern was observed
with purified full-length UBR1 versus CUP9L294P that con-
tained a previously characterized degron-inactivatingmissense
mutation (8) (Fig. 7I).
We found that the specificity of these interactions, i.e. their
dependence on the presence of the CUP9 degron, could be
4 Z. Xia and A. Varshavsky, unpublished data.
FIGURE 4. Specific interactions between UBR1 and its physiological substrates or model ligands. A, GST pulldown assays with full-length, FLAG-tagged
fUBR1 and immobilized Arg-SCC1-GST. Equal amounts of extract from S. cerevisiae that expressed fUBR1 were incubated with glutathione-Sepharose beads
preloaded with Arg-SCC1-GST, in the presence of indicated concentrations of either the Arg-Ala (RA) or Ala-Arg (AR) dipeptides. The beads-associated fUBR1
was eluted from the beads, fractionated by SDS-PAGE, and detected by immunoblottingwith anti-FLAG antibody (see “Experimental Procedures”). B, same as
in A but with Leu-SCC1-GST and either Leu-Ala (LA) or Ala-Leu (AL). C, same assay format, with Arg-SCC1-GST. Lane 1, 5% refers to a directly loaded sample of
fUBR1-containing yeast extract that corresponded to 5% of the amount of extract in GST pulldowns of this panel. Lane 2, Arg-SCC1-GST pulldown assay with
fUBR1 in the presence of 1 mM AR dipeptide (single-letter notations for amino acids). Lanes 3–10, same as lane 2 but with either AR (1 mM free Ala and 1mM
free Arg), or RA, or R-OMe (O-methyl ester), or agmatine (see themain text), or RD, or RK, or RF, or RL, all of themat 1mM.D, same as in Cbutwith Leu-SCC1-GST
and different dipeptides or related compounds, as shown. Lane 1,Met-SCC1-GST (instead of Leu-SCC1-GST); note the absence of its interaction with fUBR1, in
contrast to Leu-SCC1-GST and Arg-SCC1-GST. E, same as in C, but with UBR11–1140f, the N-terminal half of UBR1. F, same as in D but with UBR11–1140f. G, input
samples of UBR11–1140f and its derivatives. Lane 1, UBR11–1140f. Lanes 2–7, fUBR11–717, UBR1209–1140f, UBR1454–1140f, UBR1710–1140f, UBR1866–1140f, and UBR1ha,
respectively. These derivatives of UBR1 were overexpressed in S. cerevisiae as described for UBR11–1140f. The asterisk denotes a protein cross-reacting with
anti-FLAG antibody. UBR1ha (lane 7) was employed as a (negative) control for antibody specificity. 10% input refers to a directly loaded sample of yeast extract
that corresponded to 10% of the amount of extract in GST pulldowns of H and J. H, X-peptide assay (see “Experimental Procedures”) with UBR11–1140f and its
derivatives, described inG. UBR11–1140f and fUBR11–717, but not theotherUBR1derivatives ofGbound to immobilizedArg-nsP4peppeptide. I, lane 1,molecular
mass markers. Lane 2, Coomassie-stained SDS-PAGE pattern of (overexpressed) UBR11–1140f that was purified from yeast extract using anti-FLAG affinity
chromatography and used for GST-CUP9 pulldowns (see K and “Experimental Procedures”). J, same as inH butwith immobilized Phe-nsP4pep peptide. K, lane
1,2% input. Lane2,GST-CUP9pulldownwithUBR11–1140f in S. cerevisiaeextract. Lane3, sameas lane 2, butwithGST-CUP91–221, aC-terminally truncatedmutant
of the 306-residue CUP9 that lacks its C-terminal degron (67). Note the absence of binding of UBR11–1140f (in yeast extract) to GST-CUP91–221, in contrast to its
binding to full-lengthGST-CUP91–306. Lane 4, 10% input. Lane 5, same as lane 2butwith purifiedUBR11–1140f, as distinguished fromUBR11–1140f in yeast extract.
Lane 6, same as lane 5butwith GST-CUP91–221. Note that purifiedUBR11–1140f, in contrast to the sameprotein in yeast extract, binds to bothdegron-containing
(lane 5) and degron-lacking CUP9 (lane 6). Lane 7, same as lane 5 but with ovalbumin (at 50mg/ml) added to UBR11–1140f before GST pulldownwith full-length
GST-CUP9. Lane 8, same as lane 7 but with GST-CUP91–221. Note restoration of the binding specificity of UBR11–1140f in the presence of ovalbumin. Lanes 9 and
10, same as lanes 5 and 6 but “empty” yeast extract was added to purified UBR11–1140f before GST pulldowns with either full-length GST-CUP9 (lane 9) or
degron-lacking GST-CUP91–221.
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restored if GST-CUP9 pulldowns with purified UBR11–1140f or
purified UBR1 were carried out in the presence of a “carrier”
protein such as ovalbumin, at concentrations (10–50 mg/ml)
thatwould be expected to produce “macromolecular crowding”
(Fig. 4K, lanes 4–6, compare with lanes 7 and 8; Fig. 7F, lanes 5
and 6, compare with lanes 7 and 8; Fig. 7G, lanes 9 and 10,
comparewith lanes 5 and 6; Fig. 7K, lanes 5 and 6, comparewith
lanes 7 and 8). These terms refer to volume-exclusion and
related effects that recapitulate, in part, the properties of intra-
cellular milieu, where the total protein concentration can be as
high as 200–400 mg/ml (74–76).
As expected, and similarly to the effect of ovalbumin, the
re-addition of fUBR1-lacking yeast extract to purified fUBR1
also restored the specificity of UBR1 binding to GST-CUP9
(Fig. 7E). We noticed that GST-CUP9 interacted not only with
fUBR1 in the yeast extract but also with another protein that
was present in extracts irrespective of the presence of fUBR1
(data not shown). Mass spectrometry of that protein identified
it as EF1A, which functions as a translation elongation factor, a
protein chaperone, and is a highly abundant protein (Ref. 77
and references therein). We employed two chromatographic
steps, DEAE-Sepharose and CM-Sepharose chromatography,
to purify S. cerevisiae EF1A to near homogeneity (Fig. 7H). The
addition of purified EF1A to GST-CUP9 pulldowns with puri-
fied fUBR1, at the EF1A concentration of 1.2mg/ml (a relatively
low level, in comparison to minimally effective concentrations
of ovalbumin), was found to restore the specificity of UBR1-
CUP9 interactions. Specifically, in the presence of purified
EF1A, a significant binding of purified fUBR1 to GST-CUP9
was observed only in the presence of dipeptides with destabi-
FIGURE5.Measurementsof affinitybetweenUBR11–1140f andpeptideswithdifferentN-terminal residuesusingFPassay.A,purifiedUBR11–1140f (Fig. 4I)
was incubated, at increasing concentrations,with either Arg-nsP4peppeptide (curve 1) or Gly-nsP4peppeptide (curve 2), eachof themat 10nM (C-terminal
diamond in the text and a star in the figure denote a C-terminal fluorescent tag; see “Experimental Procedures”). Note the binding to Arg-nsP4pep (bearing
a type-1destabilizingN-terminal residue) and the absenceof significant binding toGly-nsP4pep (bearing a stabilizingN-terminal residue).B, sameas inAbut
with Phe-nsP4pep versus Gly-nsP4pep (curves 1 and 2, respectively). C, competition assay, with UBR11–1140f at 1 M, Arg-nsP4pep at 10 nM, versus
increasing concentrations of unlabeledArg-nsP4pep, Phe-nsP4pep, or Gly-nsP4pep (curves 1–3, respectively).D, same as inCbutwith unlabeled dipeptides as
competitors, at indicated concentrations. Curves 1–6, LA, AR, FA, RD, RK, and RA, respectively (single-letter abbreviations for amino acids). E, same as in D, but
with an equimolarmixture of Arg and Ala (curve 1), Arg-OMe (R-OMe) (curve 2), and Arg-Ala (RA) as unlabeled competitors. F, same as in C, but with fluorescent
Phe-nsP4pep, withUBR11–1140f at 0.7M, and the competitionwith unlabeledGly-nsP4pep, Arg-nsP4pep, or Phe-nsP4pep (curves 1–3, respectively).G, same
as inDbutwith Phe-nsP4pep as a labeledpeptide,withUBR11–1140f at 0.7M, andwith unlabeled dipeptides (or their derivatives) as competitors.Curves 1–7,
LD, L-OMe (Leu-OMe), LG, LL, LR, LA, and WA, respectively. H, same as in G, but with Arg-nsP4pep as a labeled peptide, with UBR11–1140f at 0.7 M, and with
unlabeled competitors GGGG, RGD, RGDS, RG, or RAGESGSGC (single-letter abbreviations for amino acids) (curves 1–5, respectively). The RAGES sequence of the
latter peptide is identical to theN-terminal sequenceof the separase-producedC-terminal fragmentof SCC1, aphysiologicalN-end rule substrate (see “Results”
and “Discussion”). I, same as in H, but with Phe-nsP4pep as a labeled peptide, with UBR11–1140f at 0.7M, and with unlabeled GGGG, FG, FGG, FGGF, FA, and
Phe-nsP4pep peptide as competitors (curves 1–6, respectively).
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lizingN-terminal residues (Fig. 7G, lanes 7 and 8, comparewith
lanes 2–6 and 9 and 10).
A parsimonious interpretation of these findingswith purified
UBR1 versus its supplementation with ovalbumin, or with yeast
extract, or with EF1A is that CUP9, a transcriptional repressor,
functions in vivo as a complex containing “global” corepressors
TUP1 and SSN6 (78). In the absence of these CUP9 ligands, the
CUP9 moiety in purified GST-CUP9 may exhibit a “sticky”
region(s) that mediates a nonspecific interaction between
CUP9 and UBR1. This region(s) of CUP9may be shielded from
UBR1 by interactions with either EF1A, acting as a chaperone,
and/or with another chaperone-like proteins in the yeast
extract, thus allowing a specific UBR1-CUP9 interaction to be
detected. Because “crowding” levels of ovalbumin (10–50
mg/ml) also restore the specificity of UBR1-CUP9 interaction
(Fig. 4K and Fig. 7, F and G), the presumed sticky region(s) of
CUP9 may be partially unfolded in the absence of EF1A or
ovalbumin. In vivo, CUP9 is likely to be targeted by UBR1 for
ubiquitylation (and subsequent degradation) as a part of the
TUP1-SSN6-CUP9 complex (79, 80). The previously discov-
ered subunit selectivity of the N-end rule pathway (20, 23) is
expected to make possible selective degradation of the CUP9
moiety in the TUP1-SSN6-CUP9 complex in vivo, leaving the
corepressor TUP1-SSN6 intact. This model remains to be
addressed experimentally.
Synergistic Effects of Type-1/2
Dipeptides in a UBR1-dependent
Ubiquitylation System—Our stud-
ies of the targeting of CUP9 by the
UBR1 Ub ligase (8, 40) included
the development of an in vitro sys-
tem that consisted exclusively of
small compounds and purified
recombinant proteins (Ub, UBA1,
RAD6, UBR1, and CUP9) (see
“Experimental Procedures” and
Ref. 67). This system exhibited the
UBR1-dependent, RAD6-dependent
polyubiquitylation of CUP9 that
was enhanced by single dipeptides
such asTrp-Ala or Lys-Ala that bore
destabilizing N-terminal residues
but was not enhanced by composi-
tionally identical single dipeptides
such as Ala-Trp or Ala-Lys, which
bore a stabilizing N-terminal resi-
due (40, 67). As with most such sys-
tems, the extent of its specificity, in
this case the extent of its UBR1
dependence vis-a`-vis polyubiquity-
lation of CUP9, was a function of
both UBR1, RAD6, and Ub concen-
trations (Ref. 67 and data not
shown).
In this present study, we asked
whether the specificity of the system
could also recapitulate, at the level
of UBR1-dependent polyubiquityla-
tion of CUP9, the previously demonstrated dependence of the
UBR1-CUP9 in vitro interaction (assayed by GST pulldowns)
on the presence of both type-1 and type-2 dipeptides (e.g. both
Arg-Ala and Leu-Ala) (8) (see also Fig. 7). Indeed, we observed
a clear enhancement of the UBR1-dependent CUP9 polyubiq-
uitylation upon the addition of both Arg-Ala and Leu-Ala (at
micromolar levels), as distinguished from either Arg-Ala alone
or Leu-Ala alone (Fig. 8). Specifically, little polyubiquitylated
CUP9 was formed in reactions that contained no added dipep-
tides (Fig. 8, lane 2). Some polyubiquitylated CUP9, bearing
relatively short poly-Ub chains, was formed in the presence of a
mixture of Leu-Ala (a type-2 dipeptide) and Ala-Arg (bearing a
stabilizingN-terminal residue), at 2Meach (Fig. 8, lane 5). The
distribution of poly-Ub chain sizes shifted slightly upward at 10
M of Leu-Ala plus Ala-Arg (Fig. 8, lane 6; compare with lanes
2 and 5). However, when a mixture of type-1 (Arg-Ala) and
type-2 (Leu-Ala) dipeptideswas present, the polyubiquitylation
of CUP9was detectable already at 0.8Mof each dipeptide (Fig.
8, lane 7; compare with lane 2). The average size of CUP9-
linked poly-Ub chains greatly increased at 2 M of type-1/2
dipeptides, and the average size of such chainswasmuch higher
than the one observed at the same concentration of Leu-Ala
plus Ala-Arg (Fig. 8, lane 8; compare with lane 5). Finally, at 5
M of type-1/2 dipeptides, the size of most poly-Ub chains
became too large for the resulting CUP9 conjugates to be frac-
FIGURE 6. Measurements of affinity between UBR11–1140f and peptides with different N-terminal resi-
dues using surface plasmon resonance. A, BIAcore sensograms (see “Experimental Procedures”) illus-
trating the binding of UBR11–1140f to the immobilized 12-residue Arg-nsP4pep peptide, bearing a type-1
primary destabilizing N-terminal residue. RU, resonance units. Curves 1–5 correspond to the passing of
purified UBR11–1140f, at either 0.188, 0.375, 0.75, 1.5, or 3 M, over immobilized Arg-nsP4pep. B, same as in
A but with immobilized Phe-nsP4pep, bearing a type-2 primary destabilizing N-terminal residue (Fig. 1A).
C, same as in A but with Gly-nsP4pep bearing a stabilizing N-terminal residue (no detectable binding to
UBR11–1140f at any of its tested concentrations).D and E, binding isotherms (derived from the data in A and
B, respectively) for Arg-nsP4pep and Phe-nsP4pep (see “Experimental Procedures”).
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tionated under conditions used,
resulting in a diffuse “band” of large
conjugates near the origin of the gel
(Fig. 8, lane 9; compare lanes 7 and
8, and also with lane 6, which illus-
trates the average size of poly-Ub
chains in the presence a type-2
dipeptide (Leu-Ala plus Ala-Arg) at
10 M, twice as high as the 5 M
level of type-1/2 dipeptides
together). Thus, in addition to the
previously demonstrated depend-
ence of the physical binding of
UBR1 to CUP9 on the presence of
both type-1 and type-2 dipeptides
(8) (see also Fig. 7), our present find-
ings (Fig. 8) strongly suggest that the
processivity of polyubiquitylation of
CUP9 by the UBR1-RAD6 Ub ligase
is increased when both of the type-1
and type-2 binding sites ofUBR1 are
occupied by cognate dipeptides.
One constraint on possible mecha-
nisms of UBR1 processivity stems
from the fact that the bulk of either
purified UBR1 or UBR1 in yeast
extracts is a monomer, as deter-
mined by gel filtration (see Refs. 67,
70 and data not shown).
DISCUSSION
Since the 1990 cloning of S. cer-
evisiae UBR1, the first molecularly
characterized E3 Ub ligase (70), it
was clear that at least the bulk of
enzymatic (polyubiquitylation)
specificity of the UBR1-RAD6 holoenzyme toward polypep-
tides with primary destabilizing N-terminal residues (Fig. 1A)
stems from selective binding of UBR1 to those residues, rather
than from the effects of a bound N-terminal residue of a sub-
strate on the kinetics of substrate ubiquitylation by UBR1-
RAD6. For example, immunoprecipitation of an epitope-
tagged UBR1 from yeast extracts containing Arg-gal (an
N-end rule substrate) versus the otherwise identical Val-gal
(not an N-end rule substrate) coprecipitated Arg-gal but not
Val-gal (70). Quantitative measurements, in this study, of
these differential affinities of UBR1 confirmed and extended
the earlier inferences. Specifically, using both FP and SPR,
we found that UBR1 bound to either type-1 (basic) or type-2
(bulky hydrophobic) N-terminal residues of 12-mer X-pep-
tides with a Kd of 1 M. In contrast, neither FP nor SPR
could detect the binding of UBR1 to an otherwise identical
reporter peptide bearing a stabilizing N-terminal residue
such as Gly (Figs. 5 and 6).
The above affinity of the 225-kDa yeast UBR1N-recognin for
cognate (primary destabilizing) N-terminal residues (Fig. 1A) is
in agreement with the approximately equal affinity of ClpS, the
12-kDa E. coli N-recognin (see Introduction), for its cognate
(bulky hydrophobic) N-terminal residues (2, 13). The relatively
high rate ofUBR1 dissociation from substrate proteins (implied
by the equilibrium Kd of 1 M for UBR1 binding to N-de-
grons) may facilitate the transfer of a targeted, polyubiquity-
lated substrate to downstream components of the N-end rule
pathway, such as Ub-binding chaperones and the 26 S protea-
some. Although UBR1 is a scarce protein in S. cerevisiae (300
molecules per haploid cell5), the UBR1-dependent N-end rule
pathway is highly efficacious. For example, wild-type levels of
UBR1 sufficed to reduce the steady-state level of a reporter
N-end rule substrate such asArg-gal to less than 5% of its level
in the absence of UBR1, even under conditions where Arg-gal
was expressed from the induced PGAL1 promoter on a high copy
plasmid and would have been an abundant protein in the
absence of its degradation by theN-end rule pathway (9, 54, 69).
UBR1 was also found to interact with specific subunits of the
26 S proteasome (81), in apparent contradiction to the notion
of rapid transfer of a UBR1-targeted substrate to downstream
effectors. One possibility is that a significant fraction of UBR1
5 C.-S. Hwang and A. Varshavsky, unpublished data.
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molecules might be associated, at any given time, with the
(much more abundant) 26 S proteasome. In other words, the
UBR1-dependent targeting of N-end rule substrates may take
place in the context of a UBR1-proteasome complex. This
model remains to be addressed experimentally.
Genetic screens, in this study, forUBR1mutants that lost the
ability to target type-1 N-end rule substrates but retained the
targeting of type-2 substrates and vice versa have yielded both
classes of mutants, thereby indicating a modular organization
of the type-1 and type-2 substrate-binding sites of UBR1. The
type-1 site (it binds to N-terminal Arg, Lys, or His) is located
primarily in the 70-residue UBR domain of UBR1, whereas
the type-2 site (it binds to N-terminal Trp, Phe, Tyr, Leu, or Ile)
resides at least in part downstream of the type-1 site and,more-
over, may partially overlap (or functionally interact) with the
third substrate-binding site of UBR1, the one that targets CUP9
(Figs. 1C and 3). We also found that the previously character-
ized UBR1-dependent in vitro ubiquitylation system (40, 67)
exhibited a synergistic effect of two dipeptides with cognate
type-1 and type-2 N-terminal residues on the rate of CUP9
polyubiquitylation (Fig. 8). This ubiquitylation-based result
extended our earlier observation (8) (see also Fig. 7) that the
physical binding of UBR1 to CUP9 in vitro required the occu-
pancy of both type-1 and type-2 binding sites of UBR1 by added
dipeptides.
Another finding of this study is that a specific (CUP9 degron-
specific) in vitro interaction between GST-CUP9 and UBR1
required the presence of either yeast extract, or the translation
factor EF1A (which is known to function as a chaperone), or
ovalbumin, the latter at concentrations that producemacromo-
lecular crowding (Figs. 4 and 7). As described under “Results,”
FIGURE 7. CUP9 mutants, UBR1-CUP9 interactions, and effects of macromolecular crowding on the specificity of interaction between purified proteins.
A,mapofthe306-residueCUP9andits truncationmutants.B,GSTpulldownassayswithUBR11–1140f andGSTfusionsto indicatedCUP9derivatives (seealsothe legend
to Fig. 4, “Experimental Procedures” and themain text). Lane 1, 5% refers to adirectly loaded sampleofUBR11–1140f-containing yeast extract that corresponded to5%
of the amount of extract in GST pulldowns of this panel. Lane 2,GSTpulldownwithUBR11–1140f andGST fusion towild-type CUP9. Lanes 3–7, same as lane 2butwith
GSTfusionstoCUP9mutants.Lane8,sameas lane2,butGST lackingtheCUP9moiety.ThebandofUBR11–1140f (retainedonglutathione-Sepharosebeads) is indicated.
C, lane 1, same as lane 1 in B, except that the test S. cerevisiae extract contained full-length fUBR1. Lanes 2–9,GST pulldownswith fUBR1 and the indicated GST-CUP9
fusions. As indicated above the lanes, all samples except those in lanes 3 and 5 contained amixture of Arg-Ala (RA) and Leu-Ala (LA) dipeptides, each of themat 1mM
(see“ExperimentalProcedures”).Lane10, sameas lane2,butwithGSTalone.D, lane1,molecularmassmarkers;singleanddoubleasterisksdenote, respectively,220and
60 kDa. Lane 2,Coomassie-stained gel of purified full-length fUBR1. E, lane 1, same as lane 1 inC, but 2%of total fUBR1 in the assay. Lanes 2 and 3, same as lanes 3 and
2 (respectively) inC,butanindependentexperiment.Lane4,sameas lane1butwithpurifiedfUBR1.Lanes5and6,sameas lanes2and3butwithpurifiedfUBR1towhich
wasaddedanempty (lacking fUBR1)S. cerevisiaeextract.Note thatpurified fUBR1assayed in thepresenceof “added-back”yeastextractexhibitedspecific (dipeptides-
dependent)bindingtoGST-CUP9(lanes5and6), indistinguishably fromfUBR1thathadnotbeen initiallypurified (lanes2and3).F, lanes1–4, sameas lanes1–4 inEbut
an independent experiment. Lane 4, same as lane 1, but 10%of the input sample of the purified fUBR1 (see lane 2 inD). Lanes 5 and 6, same as lanes 2 and 3 butwith
purified fUBR1.Note the lackofdependenceofUBR1-CUP9 interactionon thepresenceof cognatedipeptides.Lanes7and8, sameas lanes5and6butGSTpulldowns
were carried out in the presence of addedovalbumin, at 10mg/ml.G, lanes 1–3, same as lanes 1–3 in Eor F, but an independent experiment. Lane 4, same as lane 4 in
F,butanindependentexperiment.Lanes5and6, sameas lanes7and8 inF,butwithovalbuminat50mg/ml.Lanes7and8, sameas lanes5and6,butwithpurifiedEF1A
added to theassay (to1.2mg/ml), insteadof ovalbumin. Lanes 9and10, sameas lanes 7and8, but in theabsenceof addedEF1A.H,Coomassie-stainedgel of purified
EF1A(see“ExperimentalProcedures”). I, lane1, sameas lane inF, butan independentexperiment.Lanes2and3, sameas lanes2and3 inEorF, butwithGST-CUP9L294P,
apreviouslycharacterizedmissensemutantofCUP9(intheregionof itsdegron) thatdidnotbindtoUBR1andwasmetabolicallystabilized invivo (8).Notetheabsence
of bindingof fUBR1 (in the extract) toGST-CUP9L294P, irrespective the absenceor presenceof dipeptides. Lane 4, sameas lane 4 in F, but an independent experiment.
Lanes5and6, sameas lanes2and3butwithpurified fUBR1.Notethatpurified fUBR1bindstodegron-impairedGST-CUP9L294Panddoesso irrespectiveof thepresence
or absenceof dipeptides. J, lane 1, sameas lanes 4 in For I, but an independent experiment. Lanes 2 and3, sameas lanes 5 and6 in F, but in thepresenceof ovalbumin
(at 50 mg/ml). Lanes 4 and 5, same as lanes 2 and 3 but with GST-CUP9L294P, instead of “wild-type” GST-CUP9. K, lane 1, same as lane 1 in F, but an independent
experiment. Lanes 2 and 3, same as lanes 2 and 3 in F and G, but with GST-CUP9222–306, an N-terminally truncated CUP9. Note the retention of specific (dipeptides-
modulated)bindingof thisCUP9derivative to fUBR1.Lane4, sameas lane4 inF, but an independentexperiment.Lanes5and6, sameas lanes2and3butwithpurified
fUBR1. Lanes 7and8, sameas lanes 5and6, butwith addedovalbumin (ov), at 50mg/ml.Note the restorationof specific binding. L,analternativeUBR1-CUP9binding
assay inwhichthe interactionswereprobedusingcoimmunoprecipitationof fUBR1andpyCUP9his6,aGST-lacking, full-lengthCUP9bearingtheN-terminalpyepitope
tag (see “Experimental Procedures”). FLAG-tagged fUBR1 in the yeast extract was incubated with beads-immobilized anti-FLAG antibody, followed by isolation of
fUBR1-bearingbeadsbycentrifugation,washeswithbindingbuffer,andincubationwitheitherpurifiedpyCUP9his6alone(lanes2and3,upperpanel)or inthepresence
of (added)UBR1-lackingyeast extract (lanes 4–7). The incubationswere carriedout in either theabsence (lanes 2, 4,and6) or thepresenceofArg-Ala (RA) andLeu-Ala
(LA) dipeptides, each of them at 1mM. The beads containing immobilized fUBR1were pelleted by centrifugation andwashed, and the relative amounts of retained
pyCUP9his6were thendeterminedby SDS-PAGEand immunoblottingwith anti-py antibody (see “Experimental Procedures”). Theupper panel shows the amounts of
pyCUP9his6 thatwere bound to
fUBR1 in the absence of added yeast extract (lanes 2 and 3) or in the presence of extract. Lane 1 shows the amount of pyCUP9his6 that
corresponds to 10%of its input in each of the binding assays. The lower panel is the result of SDS-PAGE and immunoblotting (with anti-FLAG antibody) of fUBR1 that
was eluted from anti-FLAGbeads by the FLAGpeptide, to verify the approximate equality of “input” levels of fUBR1 in each assay. Note that in the absence of added
(UBR1-lacking) yeast extract, the interaction between fUBR1 and pyCUP9his6 was nonspecific, in that it was independent of the absence or presence of cognate
dipeptides (lanes 2 and 3; comparewith lanes 4–7). Lanes 6 and 7, same as lanes 4 and 5, but the input pyCUP9his6 was 2-fold higher.
FIGURE 8. Synergistic effects of type-1/2 dipeptides in a UBR1-dependent
ubiquitylationsystem.Reactions consistingofpurified S. cerevisiaeUb,purified
UBA1 (E1, Ub-activating enzyme), RAD6 (the N-end rule pathway E2, Ub-conju-
gating enzyme), UBR1 (the N-end rule pathway E3 Ub ligase), 35S-labeled, puri-
fiedCUP9, andATPwere supplementedwithpairs of purifieddipeptides, at indi-
cated concentrations. The pairs of added dipeptides were Arg-Ala plus Ala-Leu
(RAAL), or Leu-Ala plus Ala-Arg (LAAR), or Arg-Ala plus Leu-Ala (RALA), or
Ala-Arg plus Ala-Leu (ARAL). The reactions were incubated at 30 °C for 10min,
followed by SDS-10% PAGE and autoradiography (see “Experimental Proce-
dures”). Unmodified CUP9 and CUP9-linked poly-Ub chains are indicated on the
left. Asterisk on the right denotes a protein present in the initial CUP9 sample,
possibly an SDS-resistant dimer of CUP9. Lane 1, purified CUP9 (input). Lanes
2–10, sameas inB, but a setof independentlyperformedreactions,withdifferent
concentrations of added dipeptide pairs. Note a synergistic enhancement of
CUP9 polyubiquitylation in the presence of RALA (lane 9).
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this requirement is likely to stem from the fact that CUP9 func-
tions in a complex with the general repressor TUP1-SSN6 (78–
80). Thus, in contrast to the in vitro setting of purified GST-
CUP9 (Fig. 7), UBR1 may not have access, in vivo, to
(potentially) UBR1-interacting surfaces of CUP9 outside of its
C-terminal proximal degron (8) (Fig. 7). It remains to be deter-
mined whether the short in vivo half-life of CUP9 (5 min in
the absence of UBR1-activating dipeptides in growth medium
and2min in their presence (40)) reflects the UBR1-mediated
targeting of CUP9 directly at chromatin, i.e. at transcriptional
promoters that comprise the CUP9 regulon.
In the S. cerevisiae UBR1 E3, in its mammalian sequelogs
UBR1/UBR2, and in some other N-recognins of mammals and
plants (31, 32, 35) the UBR domain contains at least the type-1
substrate-binding site. A UBR domain is also present in UBR1
sequelogs that do not function as N-recognins. One example is
the S. cerevisiae UBR2 E3, which is distinct from metazoan
UBR2. Physiological substrates of S. cerevisiae UBR2 include
RPN4, a short lived transcription factor that regulates the syn-
thesis of proteasomal subunits (82, 83). The mammalian UBR3
E3 (its functions include regulation of olfaction) is yet another
UBR domain-containing E3 Ub ligase that is not anN-recognin
(29). Physiological ligands of the UBR domains in Ub ligases
that are not N-recognins remain to be discovered.
Although prokaryotes lack the Ub system, they still contain
the N-end rule pathway, albeit Ub-independent versions of it
(10–15). The N-end rules of prokaryotes are subsets of the
yeast N-end rule (which in turn is a subset of the mammalian
N-end rule (Fig. 1A)). Despite these similarities between the
rule books of eukaryotic and prokaryotic N-end rules, the
underlying mechanisms in eukaryotes are quite distinct from
those in prokaryotes, with differences beyond the absence ofUb
in the latter. For example, the largest known prokaryotic N-end
rule, the one of Vibrio vulnificus, a Gram-negative bacterium
and human pathogen, is similar to the mammalian N-end rule;
among 13 destabilizing N-terminal residues in the mammalian
N-end rule (Fig. 1A), only Asn, Gln, and His are stabilizing
residues in V. vulnificus (12). (N-terminal Asn and Gln are
destabilizing in eukaryotes because of N-terminal amidases
(Fig. 1A), which are absent from examined prokaryotes.) This
rule book similarity between the mammalian and V. vulnificus
N-end rules is a “convergent” one, in that it stems fromdifferent
mechanisms. In particular, theN-terminalArg andLys residues
are destabilizing in eukaryotic N-end rules because these resi-
dues are recognized directly (together with N-terminal His) by
the type-1 substrate-binding sites of the Ub ligases of the path-
way (see Introduction). By contrast, N-terminal Arg and Lys are
secondary destabilizing residues in both E. coli and V. vulnifi-
cus, because of the presence of L/FK,R-transferase, an enzyme
that is absent fromexamined eukaryotes and conjugates Leu (or
Phe) to N-terminal Arg or Lys (10, 11, 16–18). The resulting
additional (bulky hydrophobic) residue at the N terminus of a
substrate is recognized by the ClpS N-recognin, which medi-
ates the delivery of bacterial N-end rule substrates to the pro-
teasome-like ClpAP protease (13–15). Furthermore, in
eukaryotes the N-terminal Asp, Glu, and (oxidized) Cys resi-
dues are arginylated (by R-transferase) before the recognition
(through conjugated N-terminal Arg) of thus modified sub-
strates by N-recognins (Fig. 1A). In contrast, N-terminal Asp
and Glu in prokaryotes are either stabilizing (unrecognized)
residues, for example in E. coli, or are destabilizing, e.g. in V.
vulnificus, but through the leucylation (not arginylation) of
N-terminal Asp or Glu, i.e. through their conjugation to Leu by
the bpt-encoded LD,E-transferase, whose specificity differs
from that of the aat-encoded L/FK,R-transferase (2, 12).
The primordial (early) N-end rule presumably comprised a
“minimal” set of destabilizingN-terminal residues, i.e. the bulky
hydrophobic residues Trp, Phe, Tyr, and Leu that are a part of
N-end rules in all examined organisms. This set is recognized
by prokaryotic N-recognins (ClpS proteins) and by the seque-
logous type-2 binding sites of eukaryotic Ub ligases that func-
tion asN-recognins (Fig. 1A). The co-option ofArg andLys into
a primordial N-end rule during evolution of eukaryotes
involved the emergence of an additional, Arg/Lys/His-specific
(type-1) binding site in cognateUb ligases (Fig. 1,A andB). This
elaboration of N-end rule in eukaryotes must have happened
after their divergence from prokaryotes, because the Arg/Lys
expansion of prokaryotic N-end rules involved an entirely
different route, the appearance of the aat-encoded, Leu/Phe-
conjugating aminoacyl-tRNA-protein transferase (L/FK,R-
transferase) (2, 12). The apparently independent emergence of
the bpt-encoded LD,E-transferase (which is not sequelogous to
the Aat L/FK,R-transferase) enabled the Asp/Glu/Cys expan-
sion of prokaryotic N-end rules. Yet again, this evolutionary
route was entirely different from the one that emerged in
eukaryotes (see above). The two classes of prokaryotic trans-
ferases, Aat and Bpt, are largely nonsequelogous and recognize
different N-terminal residues, but they do have in common
their use of aminoacyl-tRNAs as amino acid donors and their
conjugation of a hydrophobic residue, Leu or Phe, to N termini
of their respective substrates. This conjugation results in the
binding of (thus modified) substrates by the ClpS N-recognin.
Given these constraints on possible evolutionary routes, a
parsimonious scenario is that a primordial N-end rule pathway,
which targeted substrates via bulky hydrophobic N-terminal
residues (but did not recognize, as yet, other N-terminal resi-
dues), emerged in a common ancestor of prokaryotes and
eukaryotes. Being sensitive to protein folding and recognizing a
“topologically” universal determinant (anN-terminal residue is
present even in dipeptides), the N-end rule pathway is likely to
have appeared early, possibly coevolving with primordial ribo-
somes during the emergence of translation-endowed organ-
isms. Later expansions of the N-end rule pathway kept specific
N-end rules similar in all organisms (presumably because of a
selection pressure forN-end rules of certain compositions), but
the machinery implementing this pathway evolved divergently
in prokaryotes versus eukaryotes. In particular, Ub ligases and
ubiquitylation/deubiquitylation emerged (or, alternatively,
were retained) only in eukaryotes (12, 84). In addition, the task
of recognizing additional (basic and acidic)N-terminal residues
in later, more elaborate N-end rule pathways was solved quite
differently in evolving eukaryotes and prokaryotes, as described
above. Moreover and significantly, the evolution of N-end rule
E3 Ub ligases (N-recognins) in eukaryotes expanded their rep-
ertoire of substrate-binding sites beyond the N-end rule. One
example is the third substrate-binding site of S. cerevisiaeUBR1
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that recognizes an internal (non-N-terminal) degron in CUP9
and is designed to be controlled, allosterically, by the occupancy
of the other two (“N-end rule”) binding sites ofUBR1 (see Intro-
duction). A landscape of selective pressures, quasi-neutral
mutational drifts, and stochastic fixations of changes (85) that
gave rise to these differences between eukaryotic and prokary-
otic N-end rule pathways remains to be addressed in detail.
This problem is made particularly interesting by the fact that
although the functions of theN-end rule pathway in eukaryotes
aremany and partially understood (see Introduction), the func-
tions of prokaryotic N-end rule pathways are still unknown.
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